var title_f2_10_2208="Cystine crystals";
var content_f2_10_2208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing cystine crystals",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing hexagonal cystine crystals that are essentially pathognomonic of cystinuria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2208=[""].join("\n");
var outline_f2_10_2208=null;
var title_f2_10_2209="Decision tree for diagnosing schizophrenia subtype";
var content_f2_10_2209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F56991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F56991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Decision tree for diagnosing schizophrenia subtype",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 526px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2209=[""].join("\n");
var outline_f2_10_2209=null;
var title_f2_10_2210="Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes";
var content_f2_10_2210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2210/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2210/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2210/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/10/2210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 56-year-old woman is referred to you for management of type 2 diabetes.",
"   </p>",
"   <p>",
"    Nine years ago the patient experienced three to four months of polyuria, polydipsia, nocturia, dry mouth and blurred vision. She had habitually consumed large quantities of orange juice and ginger ale, and had increased consumption several fold when polydipsia appeared. She weighed 188 pounds, was 5' 5\" tall and had a body mass index of 31.3",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    A random glucose level was 237",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and the hemoglobin A1C (HbA1c) was 10.7 percent. The patient was treated for diabetes with a no-concentrated sweets, low fat diet, including substitution of diet beverages and water for juices and sodas, and with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    5 mg by mouth once daily. Over the next six months, the A1C fell to 7.9 percent and the patient's symptoms resolved.",
"   </p>",
"   <p>",
"    Over the ensuing years, the patient's weight increased to 199 pounds, the BMI increased to 33.1",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    the A1C level rose, and the use of oral agents increased. At the present time she takes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    10 mg by mouth twice daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    1000 mg by mouth twice daily. The fasting glucose level is consistently 150 to 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3 to 8.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and the premeal values are in the 200 to 230",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1 to 12.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range. The A1C is now 9.7 percent. She eats three meals daily, follows her diet and counts carbohydrates. The nutritionist advises you that the patient is doing all of this reasonably well. You conclude that the patient is a secondary failure on oral agents. How would you manage the patient at this time?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Add NPH insulin 20 units subcutaneously (SC) daily at bedtime. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a1?source=see_link\">",
"       \"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Add glargine insulin 20 units SC daily at bedtime. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a2?source=see_link\">",
"       \"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Add insulin",
"      <span class=\"nowrap\">",
"       70/30",
"      </span>",
"      (a mixture of NPH insulin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      in a 70:30 ratio) 20 units SC daily before breakfast. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a3?source=see_link\">",
"       \"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A3\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Add NPH insulin 20 units SC daily before breakfast. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a4?source=see_link\">",
"       \"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A4\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4107 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2210=[""].join("\n");
var outline_f2_10_2210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a1?source=related_link\">",
"      Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a2?source=related_link\">",
"      Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a3?source=related_link\">",
"      Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?2/10/2210-a4?source=related_link\">",
"      Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes - A4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_10_2211="Central squamous CA gross";
var content_f2_10_2211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Centrally located squamous cell carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilobectomy specimen showing a centrally located endobronchial squamous cell carcinoma. There is associated post-obstructive bronchiectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2211=[""].join("\n");
var outline_f2_10_2211=null;
var title_f2_10_2212="Chest wall extension MRI I";
var content_f2_10_2212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61630%7EPULM%2F67306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61630%7EPULM%2F67306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung carcinoma with chest wall invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted section shows a large soft tissue mass filling the apical-posterior segment of the left upper lobe (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung carcinoma with chest wall invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 299px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAErATYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwf+tOX/69IvXvSr1oAkXjHB/wpfp+lIOtB6Dj+lACnoetRH1x/wDWp5I56elMY4z6UAA/+twKdnPpURPPPanDIHf8DQA5j/8AXpAfQc0HmgDA+vagBuPbinpyeev60jN/9ahff+dAFkY284zQODzwaarDvx+NGcnpj2oAcT2zTicDn16dc1FuwR1r1z9nLwbD4n8XSahqUBl0/SgJArD5XmP3QfXAyaAOt+DHwvtbDTP+Es8bRKpA32ttKM+Wo6Mw/vH07Vi/Ff4iap4pubfw74eEsUU8u3ahwXzwBx0Hr7V6h8a9QMCRwzSNFpsEW+ULxluwrlP2dvCBv9Su/F2qQZUny7IMBgc5LAflQBbXwNoXgLR9HXUEWbUZFBlcjJZ+pxWzpOsLdOYrK0CQRk8kYzXd6zoMGvatuvULRW2AvPGepqr4psoNF8PyPp9uFxncQKAOD1jxPfZ+RgEGRnOMVV8O+M9A8N3Ek2pSGS7m4Y7dxXPv2rhtRt77VfMktpXSHJOM4qh/wjkEi7rpSX7sT0FAH0foupeHPEtm3kGCRpOq9647xn8PIlVri2iQxAcqB1ry7SdJv/Dupw6jo80n2eM5Khs5Hevo/wAH+IIPEGmRytt84cMpHNAHzPrXheMRTO8ZtwnQYwM1J4D8RXPhK6VNRaT7K7/Kn14r6b17w1YavblJYUR+oZV7+9eP+Kfhz5NvdCdFkd+YQDkL9KAPZfDV/BqulR3NuQyP1Hp7Vy3xS+G2neNNFeKOOK21KP54Jwv8XofauK+DfiC50fVP+Eb1ANzgq7D16fjXulAH5665pN5ouq3WnanD5V5bOUdeoPoR6g1nHqfSvrX9oj4dp4g0KTXtKh/4m9km51TgzRjqPqOor5MYYAyTwMcnJ/H3oAQf5yKTODSf54ppJ4x+lAAzcYpoPfP60wkY9qVT79PQUAPY4/CmGlzwM/WkY8c0AMI70hHpz9aUUh/LigD239kX/kpOpdcf2TL/AOjoaKT9kX/kpWpev9ky/wDo6GigDxletKB9MU1TyOfrxTlzgdKAHDr/AJ4p2cD0FIucYI5pPqeKAFP0/CmEYHfP1p3bH+QKQ9DQBGev+RTgeeeRTTTgc8+9AAfagHI46duKOCOc0AcD86AEOdxPvSqcUYGcfypw78ce9ADlwOKcOD+FMGB/jUsYBwAeT6UATWNtJdXEcUCmSaRgkaKOWY9BX2/8KvCsXgrwRaWThVuCvnXL4x85GTn6V4b+zP4Zi1bxPPrM0Qa30xQsZP8Az1buPw/lXuXj3VmaP+x7En7RKR5zD+CPr+tAHnXjst471hdOjHl207qg9So717N4c0m30PRrXTrVQscCBeO59a8u+Hmly6r8QL3V4jt0ywUW8Yz99wOo9q9cihIkeSQ5Z+MDoBQBwWq+KrzTLy98uEMvmMFJBxipvDPjW11xn07V4lhlf5cPwGFdJrGjRXMJIwMHd0rgdf0CK+kXyAI5Yv4145+tAFrxJ4LS0u/temgfZzy6f54zXIajaCFZkaBxkZG4Z/lXWeFtU1BLkaTdkyRZ++Tniu0160sRpcissYx370AeK6fvNsUxhBkH1rZ8IXsGlzvsfDHtnAqPUbA/bc28kQt9mSP4t38sYzVCSxE6F0fEg4FAHoq+L5rTMk+JIsZ5NYmveN7a8MbFQoBx1rk7H7RLcC0vAxQ9COa35PCsZAkkClTzQBmX90jalDqGmou4AF8Dnr617ZpFybzTLa4b70iAn615HpujP/aIihIEXU89K9C8P3TWc32KcjyyBsbtmgDpHVZEZHUMrDBB7ivh/wCNHhZPCPxAv7K2V0srgfarYN2VjyoPcA8V9w14N+1joklz4c0zWIowwspjHMw+8EccfhmgD5Zb7x/lTOw6U+QfNzgUwnj/AAoAafrRkZ5NB4zSD19KAHetNzwMelL07cCmk+tAAf5elH0pPrmgUAe3fsi/8lJ1L/sEyf8Ao6Gil/ZG/wCSk6lj/oEy/wDo6GigDxUZ/Glz25x/KkA+lL3oAcCDmlpO1APPH86AHUUg6UdP8aAGEUvVufxzSHPvTtv0xQAhGeaVemaDgHB5xR6Y6/zoAPr170vGeO36UY9M0Y7UAO69+9PDFQSoJOMAe54/rTUwwJDA+9dt8J/CkvivxpptoUY2kcyzXDAZARTnH40AfVvwf8MQ+D/AFhattWaRPtNy5GMuwyc/SsbxCL/UZZ7nTbV2mvG8qE7cfL0Bz2FdV471JbLT7axQhZr+UQJ7Dv8A0/Otq2SLTNKj84hEgi+Zj2AFAFTwposHh/RoNPhwXALyN/eY9TWxXM+DNRudZk1DUriNooXkEdsjdox3/HrW/aSSSxs8oC5YhQPQcUAPuEaSF0VtrEcGvMda0zVrK9k2kFHOd2cDFepVU1SxTULR4HYruHDDtQB4zNqlzZ3QkhXdgYJqSXUtQuIW+0Odr9ia7afwHAFdorl2f7wBXvXMXlobfaHgYquQfloA4fU9WubW6ACsYj2xnn60ul65Z3JYPIElU8KTjca2p2tpHdJIlIzggj9K5/VtHs97z2+5J8Hgd6AO60K7tNQmRF2tL09K6G6S4VJkm4GPlx2rw3wVq93p2ulbrIdsiMtx3r6ASZLzw8sk5zJtyCKAOMjlubeaRIn3Pg5I7fSpPCusTaiJUn3tLDJgHHXmoJWERd1OSxxiuu+GmkW9rFdXA2NI5B6dMkn86AO5TIUZ645rivjVpg1X4YeIIc7WS2aZTnuvP9DXbVz/AMQkifwJ4hW4BMRsJ92OONhoA+Ac7o1YcZUVG3v1xUi8QR8ggKMH19KjPTj60ARng4zz6Uv86Q9fejt7+9ACk/nTTwM88U7gjrmkNACY7Gj1J780uOKOR7UAe3fsj/8AJSdS9RpMv/o6Gik/ZG/5KRqP/YIk/wDR0NFAHjA78dKQ9f8APNA6/wCTS9z9e4oAcAOaTt/nmgdST09c0cf480AHf+dHf2o/P+VJ69AfrQAuM9aUfd44/Cmnrx1pRx0oAD0FOxnoKQ/r+tC+2DQA4D1oxjOM07ocikxke1ACwx4URxqBnnA9a+rf2YfDMmmeHrzVrlQHu5NkQxyEHf8AHivE/gz4Jn8Y+LoIyuNOtGEt256EA/cHqTX2PfTW2h6KxhRYoYU2xIg4z2AFAHMx/ZvEvjW6jmBVtGdRHjuepP51o+N7kSW8Omof3lw4LjP8IPQ/U/yrO+HOyHTNS1O6KeZLMxeTuQKp2VtN4k1DVdQiYrLDlLcE9/4R9KAIfHOr6xpM0Nto0B4t9wC8bm/Cur8Bz6hc+E9Pm1eLyrx0y6enPFct4FHiW+14z+JbMxC2QxAnHPoa9IoAKKjmmjhXdI4UVmXWqiNHkR0CDgbuefwoA1XdUHzHFVLw2kimOYK24dQKy55XubYzQvhR0J7elZFpLdahG9vGSVH8fp+NAGJr2gRo8lxbNlskgAY47D8K43UGSz2y3CHcThVxmvVFsfsnymRWJP1/SqGraDZXqgSxoHxzgdPSgDx7WooNWtv3GI7iN8hh1z6Cux8G+J1Okm1vVy8QK5Hf0NUdW8Pw6fdLJCxZSduFOc1WudPFtsbZhG5JHFAGxbXIluWdlIRzhfSup8HXL6NrZs7libe6X5HPRW9P1rjNOnieR4CoRl+7xXU31tLdeHw64E8BDgjuKAPUKo67aC/0TULNl3rcW8kRX1DKRj9a4rR/EV14s1fS9P0yaWC309Vu9XmQ4JbkRW4P+0QXb/ZUA/fr0OgD86b62azup7Zxh7eRoiD1GD3qm3SvQ/jtpkWlfFDW4IIzHHKwuAMYHzjJxXnje9AETdaB9O/+fpSZ7c/SlB//AF0AKPbgUE0fp9aUdc0ABxzTSf8AJpx/lTT+lAHt37Iv/JSdS/7BMv8A6OhopP2RP+Sk6l/2CZP/AEdDRQB4wp5444zRkdAfyOaAfpx60e2aAFBOevJpSff8qb9BR2JzQA7I+tN/AZoHWj6g0AHbj/8AXThg565B703tzzTlOccmgAzx1GPWnqKb04J5HSnL15xQA8dKs6bY3Wqaja2OnxNNd3MgiiRRnLGq69AM819L/syeBEtraTxVqCBriQGK0BH3F/ib6npQB6p8M/Blp4J8M29hAoa7ZFa6m7ySd/wGTiqnxAuHumjsbVvMfaQUU87jwK2/GOtf2NpZaIbrqb5Ih6H1/CuK0K9ij1lLqYszRIWkz3b60AQXVw+i2FppCEny4zJcADknGRn8a7/wfp/9naBbRuP30g8yQnrk81w3hdf+Eh8SyzzJlWYyyA84XsPzr1PpQAVXvruO0hLyOoOOATjNY2q+KrGzlkt438y4XjHYH614d8RfidZyzyxRSMbtAV+XoDQB6H4h8SzytMoZAvbHQVVXVkexjkaQSRryQK+a5/E+sai62sU7kSuFAHU5r6F0O0Sz0axtGUuI4gZXPPzUAS3Gr311i2gby7RjhmFWotV+zx/Y7NgY4vmeTFUzAs0Mg4WNz8o7026soo4jbxt/rByw60Aar61JKySK+7Hv1rSl1i2eyFrK+LibowNeeyQXcTNHbnMfQE8/jU0QfzYEMbyzA/fDKNg9Tk5I9hk0AdnBo6W1qzXjGQsfk3GsvVbQWxKTE7WG5T6Gpn1gzWqREggDCsDxxWHc30srhLl+V4B9qAK9xBGrK8C4dfmxt6/U1c1DxQ2m6M90qCe44gitR96aVuET8T1PYAntUMLx70aIcA446GsW0hfVPEba7EAdJspGt7QY4kk+7LMPpyin2YjgigDqfhEX8N+IJdGu5lll1AG6llHAknPLEe3YDsAB2r2avAPENy1pPp+t2Yw9pKu76Zr3ixuVvLKC5j+5KiuPxGaAPmH9rfTY4PE+iajGNr3Nu8UhH8RU5H6GvAW6nA/+vX1t+1dowvPA9lqanEmn3Q7clX+U/wBK+SH6859eaAIyeOvWlHXPamn8aUGgBRyM9qcOe9NHtS84zQAH8qQn14pxx05plAHt37In/JSdS/7BMv8A6Ohoo/ZEP/FydSwf+YTJ/wCjoaKAPFxSn1zSZ6nj8qX34oACOeeoo78EUdPpS+nI69+/tQADv15pMYx/nFKPrQc8nFACenc+lKMjn8KOox2pR04Iz04oAX+VOSmgYIqRfuc0Add8LvC03i7xfZ6dGp8jcHnYjhYx1r7ejS00PRwkKCGztIsKi9lA6V5h+zl4LHh7woNVvYCmp6l87b+qR/wit/4q62LOxg0+Ilpp2DOB/dHrQByPiTxBPfFr4g53HykPYdhUSmUWUP8Az9XJyVpNOshqk32iddlnajPsWxWzpmnsZ4b1uZQw2Ie4oA6/wlZxaBobTXmElkbc/r7CqXjTxPDZaVcSPcrBEE3ZJx2rifiT49Wx1CKJiRHEuSuP4sV4D8QvF114mvVQyMtnH92MHhm9TQBc8V+ObnUbmZrF3j38bwcHFcQzlpCzNljyxJ5NRck9eadwAPXPNAHbfClEm8ZWUTruyGPI6YxX0tZTpEu2NRtHBOK+Z/g62zx9aDGWMUm0flX0TDJ5Yj2cKTlwPegCwzQgyynAhXkDtn0qK4Nm9i9xO5SCNTKzqhYqo6kAcn6Dmop7TczIr/uH54PAFV5pEEYWB2WOHksnb8aALBaJoYpoA/lyIGQOu1seuO2fQ81SeBHm8wfK2ME5xU620jsZWZgDjGetSGBZZhDnBHf1oAreZE0TREhWA64rDmtmkn+d8Y/Wugu7aHe0TMQ6nIPTj+v1pJrZGVHlUqRkCgDwz4kfEi50LXrzQLeBBbiKNHuYiRPHuALFecZ2njpzg17l8Pm0/wAR+E7IaIq/2eLceSoUjaF+XaR2wQRXjcfwyfX/ABtrPiPxLG6aULp1t7bo04T5QzeifKMdyPbr7R4U1W30KCFAkaJwqKowNvYD2oAy57Ka503U9OkTE8ak7WOOncV3/wAGtWbVvAlkZD++tiYJAeoI/wD11meL0jjv4NWsxmO4QLJt6EGq3wUifT7/AMS6cT+6F158Y9AaAOp+Kmj/ANu/D/W7FUDyNbs8YP8AeXkfyr4FbIyDwwJB/Div0imjWaF4pBlHUqw9Qa/O7xJatYeINVs3BVre7liIYcjB7/nQBlHrj3pR/wDro7cfTNIKAFApRj0pvueacO1ACjgdP8RTR24pT09qQ/hzQB7d+yIf+Lk6l/2CJP8A0dDRR+yJ/wAlJ1L/ALBMn/o6GigDxcdTS/U00cHt+NL6n9aAF7gUdqQ9+1KeKADvS9+f/wBVJnn2oPJyMmgBR060q9Pw7YpvFKuMCgB44rvfg74Ok8WeL7GJ1JsoJBLOfYc4/H+lcGoyRnmvsT9nDwt/YXgSC9uFxd6h++bIwVXPAoA9WjRIo1RFCoowAOAAK8j8TXy32uyuU3vIxht/w4zXpfiS9/s/RLq46sq4UepPFeS+DLxdQ8dRRSj5bRPNGR3NAG/rFnFo2mWGnSOA74km7Z9qyNT8QCyjm1NwIra3XagPGad4n1S2uNZvLy8k2xwE4B/ugV88ePfG954nvfLiLQaZEcRQg/e/2jQBn+LPElzr2pS3Eg2oWLKO45rAJLE5OKax6jv1pOvU0AAAJwDn8aXODgmhiATgc0wHJ7A570Adh8K7trPx5pkkaBnctEAfcD/Cvpq3MXlkkDJGG6dK+UvBks8XinTjZruuTJiMe9fU3huO4Wwt5rmPMr8SJjP+TQBfksPOi/dPiMnGTSpaWlgoicZIA/E1t21vEY/IXIQ8/jRdxWjRKswBZO5oAxbu2luI/MgGE4AHtVSaNLcbJDiXPH+fyrSvJJLNVEZyX+6PSsa8RrgqWJ89e39aAK1u0c28ynDgnBH86gubpoZG88Dy1WrKRJgQ55XndVW8h+077d2AHc56+/vQBkNdzeUyly9vI3ylu35dqr6hGGtmO/54cFcc0+eyeAiCY/uh9xgcYpfDzRS6pdafKdzxrkselAHVaHNJrHguRX+8gyo9MVb+FlwJvEF7KessW38Qau+FNIEOnzrEwxIGGAfUelcr4fum0PxUYG48mT58dwTQB7hXxj+0r4abQviXdX0YItNYQXSHHSQDa4/EgH8a+xdPvYr6DzIT0OCPQ145+1lpi3Xw5gvwgaSxvEfdjkKwIP4dKAPkMjBPpRSyfePfmm0AH5Uo6/8A16aTz7UAn0xj9KAJPxptKPakJoA9u/ZE/wCSk6l/2CZf/R0NFH7In/JStS/7BMv/AKOhooA8XXI5HOKUdcA9O9IOtAHPBA/pQAHnGPpS/wBe1JnJ554pf8/U0AHpjvxmjHbuKDS/w/yyaAE/GnYOO1N656etPH6ZoA674WeH28S+ONLsiheDzN83ptFfdVrDHbwJBAgSKJQiqOwAr5+/ZV8ObbC+12dBlz5UBI7Y5P0r6HoA4b4qX5h063tIgGkkJcrjsO/865H4c6amnxapq12R9oYYBJ457VN4+1hW8QSBULMxFvFg5zz1Fad5ZxaXp8NlPIS5QTSjPSgDxv4yawsW+xifEjjc59jXipyCSOldb8Q7yLUPF2oywyBoQwVWB9K5Jj1oAb/n60gIzSjrx3pOaAFOAMd6FPOAOaRvT0FTQqsvy7gjKM/WgDqvhfYXMnjvRboRN9mtLgTSvj5QozX06msBneSKMbGJGMdBXzl4I8W23hrTJLW4jaV7iUFpFP8Aq1r2XS9QjeGKaBxJbzAbGB4xQB1yaoLVPOXDbiMCtDzoJoWdsh2Hy4riTaS28rziTfCwyB7/AFrSiuJGjD4I2jB+nagDUBUONxLHPHNOkhNzE3lf6wHOccgVm3GprHtWCMNgcn0pU1HKkp8smOR6mgCpfo5jMUfEm7G41nzyBCBK37xOuKvTXx8s3BXBXjGOSazpmjIM05++Mn2oAZez+dbHeQAq5DCq+ix29pY/aZdv2gsDvA+8P8OlYfiI3Fnbq1q3mRuScDiun+HtlDqdmg1ptsuQY0Hf60Ab/hPVXGrxW07nbcyAoDXO/FIro/jzcnH2qAFfciuwv7Czh8Z6XbWqgCDDNjoPb6VmfG7TVmvtL1EjPlKV5FAGl8GNWbUk1NXOTEVB46da3fi9pA1v4a+IbLYHdrR3QHsyjcD+leafADURB4g1TTXA86UmQ/QV7tdwi4tJoWGVkRkP4jFAH5uknaM8EAA/XvTSf/1Voa9amy1rUbUggwXEiYPbDGs4/pQAh6UDOaQ+1J34oAkzn1/OgH0Jph5ooA9y/ZD/AOSk6l/2CZf/AEdDRTf2Qjn4lal/2CJf/R0NFAHjIzR3pO9KOf58UAGeelKOnHT+dNHWnA5GeeeaAClHTPpSDmj+H68UAKKt6dZS6heRWlspaeZgiL6k1UHU16z+zj4d/tvx6k8i7oNPTzm9M9v50AfU/gLQo/DfhLTdMjUL5MKh+OrY5rT1q7FhpF3dMcCKMtn37VcBBGQeDXG/Fm8Nr4SmUZzK2049KAPM9Df+1PE9rIw8wL+8z6HvVH4xeJzaaPfSxSEXdy32dB3C9zWz8N3R7ieZk5VMdOOleMfF27eTXyGPyKTsH40AcDIeM5JJqHPYmnZ68U3r0PFACjr/APX60ckjPX1FITSdxjjmgBT19/ekH3sY/Kn7Tgn86Yv3+Pr0oAnMDrCrsDtY4BA717J8JJ1vNHFlFOGNu5+Q9VzXk1tMBAYJhuiznHcH2ra8K60nhfWodRtnZ7WT5JI+4z6igD3mye6S7lhmOUAygPIJFadnJc3Fq0YjGGO1ueBWzpkNtqlnBdNhJFGcnjINMlWSJZEhQYOTu6YFAGLc+fYxEJHvxySBUMTxSxxy52yZ5HTNas0NyUUBS6NwxrJv7WPeynKhfSgCO4Y3bKkbBTu6CoL20FwzW+75R949P8//AFqhtgsFw9yHwAPkUnrSW9+ux453CTu25vlzlfT2+tAGOrPbaqttIxkReATXR+FHt7XxPHf6jJts0JAGeM/Ssi/iS5I8kj7Qg69zWDZal52rnRtQfbBMCQ+f4h70Aeq+Jb9W1aS400biwyH9RUst4PF3hSW0kIW5hJOev61geGtA1DVYwhm2QIxQE9SO1aVto7+H/Ev2OOYtG5BY9cg9f/1UAVPgZ4durXxBqup6hFtcr5cZPXGa9sY4Bx1A71RsUihm8uBFUbckjvVq5fZHmgD4D+JsH2f4geIo/S7ZvTrzXLnpXb/GnB+Juusm3DSg/p0+tcRmgBppvenNzTehHegBfWkHSgcDr+mKAOOlAHuH7IX/ACUrUuP+YRL/AOjoaKP2Qf8AkpWpf9giX/0dDRQB4wOhAFL1pARyc4GaX2oAWl9/603vTvxzQAUpOc0nej/JoAVRz/kV9U/sp6J9k8M6lqsiENfT+WpP91BivliFGkdY0Xc7sFUepPFfe/w50RfD/gvTNPjGGiiBb3Y0AdMAFGB0FeafGadmgsbSMEs7ZPFel15F8XryQazbRQKXlUBRjkLnnJ9BQBV+GdpJNqV88q7LSJdp46mvnr4qXYu/GGoeWMRRSFFHtmvpDRNRNlZizYbT5ZkmcdjivlHxBdfatav7hfuPO5X6ZoAzccn260bgW7e9Ic96T+WcUAGeTj14ozgD0FIOMU4Kc/rQAo4BYHmjawY8dqcBxSs5BBI46CgBYiVdTyR1xVy2to5ZcM2EYg7TVSNsMTjt0oFw25XUkEdCKAPpLwZ4phvDb6fIwjfYFzu9Biu7VWXyo0IaMjbuHNfJmj6xIJ4QWZX38P0wK9X8M+Nrmwc2d45kU8xuD2oA9YmlkhcRooZB2rLvJ4HcpN97PKg8nFcbrt/qusALokwHyHcNxzj2xWbZ3V5FaRSXmFkj+Rlz/k0AdxLpkV/brJEdoRsjB61SvdPWKItKn7/HBrnLvWpbGaFY5wYyQxG4cVWvPiJAylHVmlDbSeKAHX9xOk8TQqUkUkNkdRWTaaadU8RWd1cSCG3t5DJJ6n/61YPjDxFPeQKbRirDoynGa5WDVL07fNnfB+8M9aAPqz4eXyanqt+i3CpZglYscZIqPWIrqx8QX8tw5eIsrRMfQV4r4a1SUrbx2UjRvGwdlz2rt/EHiqW7kjRm2+XwQTnNAHuui3kdzHbyZALpgDNaF+uYg2cYNeW+ANbFwluZ8qsDYGe4Nen37h7CRgcDGQaAPhv4z2Utj8TNdjnUgvIJV91IGK4fv1r139ptF/4WDbzDrLYpn3INeQd6ABu+eab35pSabz+FACn3NA6f/WpD1oH6etAHuX7IX/JStS/7BEn/AKOhopP2Qv8AkpWpf9giX/0dDRQB4yM5o478UDjqPwpfXn8aAE5yfy+lOPpmkPXseO1OHscc0AJ1pQPXPFA684pR16fSgDtvg1oR8QfEXR7ZkDwxS+fLnphea+5Itwd1KBYxgIQc7uP0r5t/ZJ0dJLzWNYc/vIwIIxjsepr6XNACL1rw7x/d+Z4oeWHLszbIx/8AWr2fVJTDp1xIvBCE14oI4ZtYNxcMGCklT2oAzNclvLHw3f3WSWWFg7dwccV82sMqvvz1619GePrw2vg/UMYZLo7QDXzq/JGDnFAEY65NIPUUuBjgY/CpFjyOce5oAh7+2c4p4yFLd6k8rOO5zwBUskIiRXIBJG0Hv/8AqoAgXO4nnApWY4H5VKg3bVAGDTZ42XqD8vH1oAjkbCgj6cVEXGTlalKHbk1Ft4yeOfzoAfHKY5AyfTrg1OLy4wcSPkHjnoKqo+0HPXPFW4JUkG0qAGGAfSgCzbeI9Us9psr2eJx3VqlHiLUpyFnu5H3NuLE9/Ws6ayZQ8vOwcE1XRGQ5PTPFAGjNd3fnGVp5CD0+aktJnkOHJyxySTzVaVnCqqHA61LaYkkYkAAe9AFidJ4Y/nJMfY9qjuNxiR1PPBB7Gp53ZFCMcx5yD3zSJJudreXGT900AbnhjUmt9S08RxlpZiIyPUmvc7v4dWmqiGSe4EV2Yt5TfjHGea+dNLuJrO8iniGZ7dwygjpX0h4cvv7S8Nf8JHNcZvQPs3lj+A5wR9QeKAMPTWms7q/s4yQ9soOV6cGvbbG9Nz4btyMlngBJ/OvEFWVvFWqQuP3j2YYH3+teueDb2G88FW5jILpGY2xwM5NAHzf+0sijxLpDBgSbQqT64IrxvnPSvaP2jwDf6LIDk+VIrH8Vrxc0AIcU0df/AK1OJOKb3oAQ0opDQMY9vagD3L9kH/kpWpf9giX/ANHQ0Un7IP8AyUvUv+wRL/6OhooA8aHfGTSj60i+9KOvrQAvfr+maPrwKTv3zTxxyOB60AJxTgM//qoHSnRj5lA65xQB9h/s16Olj8O7S+xtmvCXb3Ga9ZPSuX+GFqtl8P8AQYEXaFtU4xjtXUEZBBoAzNfiM+j3USnBKHk144jQCw8uM7mMpRmP1r2HX2CaPcszsAF5wOvt/SvJPDtkt0k4PRZGcZoA4/4pywx+DbjzCRscIinOdx7+1eDMOcd/616J8Zrx38QJZpKWt44wwToAx6n6156R78/yoAZk9evoacCcgZ4pCOcnNPjQnAA59KAE3YbI7dPepA5cncMrSm1lIJWNyBgdK6HQfDOp3eH+xyhAcEsnTPf6UAZNtGsTZb6g+9LqJxs9epr0LS/hlqUt2huhtt85JAPSp/HXw5msNPa6sAX8sZZMHOP8aAPJT/q+epNV5AQdvQVZMcgzlGBHUEYxTGgm27gkmAeTt6UAVx7jgfkas2qBx12svI96hdHHDKR+HJoVmzuX+DsKAOgt72BlMMyf6M4w3sfWs/VLBoAJIJPNhzwR1/Go7G7RGIuYy8TH/OKsS3MduSbdy0b/AMLDtQBnb3fqMUkO4PwTkdqsKTICWH3easx2yyJ9pDADHI/z/nrQAm7z4cNgMKrTH5lB++vSrZVGxswpA5FJLGrRCYA71bBFAFi0bJSdgMsdrD1r3n4Nums6FqFhIxE0R7nIHGRivArLMmVAHJ3V6r4K1iXRvCfmafExu55ChYDBA6cmgDecvZeOIhdcLPE0e4dDj2rs/ha0kKavZSkGKORmT6dv615n4immeTQbl2zJFOFdvqRXqXgZz/b19a9DLHkZ9xQB4v8AtDqfN09gDhWkAP5V4uete7ftIQ+RDp0bLx5shB/KvCGoAQ02nGmDgigAP5UCg9f0pQeDQB7j+yDj/hZepf8AYIl/9HQ0Ufsgf8lL1P8A7BEv/o6GigDxoUozx/nNC/nSgc+lAB+P9KcPwzTTgdcU/tg/pQAD6DrxU1ou+6hQdS4H6ioe1WtLGdStOf8Alsv86AP0B8MwLbeHdMhQYVbeMD/vkVpmqulD/iV2Y/6Yp/6CKtUAcp8Q7uS10Ixwf6yZsKP515fY+JLPSHkt7p1VpF2EehNeifFC8Fnp0MpXO1sivmW6b+0prua5J3zSkAjjbQBn/Fu2ig8Vu0EnmJJErj2ricfgTXReJ3M+p4kYOY4xGOOuO1ehfCP4RXXiMjUNZBt7EHKxleX+tAHmujeGtV1g5sLOWRR/EBx9K9R8J/BjUbjT1ub5WWZz8qD+EetfSuh+HdO0ayjtrS3QJGMAkc1r4xQB5f4X+Fun6dbRC4gQuuG5AJzXeW2gabbweUlrHtPXjrWpRQBVTT7RFCpAgA9BVW/0HT71GWaAYYYIHStSigDz2/8Ahdoc85mW1RmKhcN+PP6/yqWH4a6OkTQm0i8pwCRgda72oZbmKIgO4BoA8/u/hfoUkbj7FFgj061kz/CPw9EmI9PhDMvzYH3q9LfWLEOUaZemfrUq3EDglCpAH5UAeJav8FNHldj9lcRGPIETYOf8a4HX/gvPDbNLpU0rbf8AlnLyT+NfVAmUtk42jrmmpBFKGcJ8oPQDrQB8MX/hHXNIDPPZyEHK5UZrJlSeGJUdWRwCWBGCPrX3bf8Ahm2uXVgOAclSOtcF4v8AhjY6pLPPHDsd1xwMc/5xQB8pKQ67kOGHY8VO242wZAcj7y4rufEvw2v9AkWaHdLEOcFefpXOSIFfcE2H+JcUAZsP7pxLEP3RXkele2fByztLXwRf6lq0atbxSMyg+leOW0QF40PSKQbhntXsnwV/0jSNU029O+3gLSMvquCaAE8Z2MIspZrbPlLJFOq+mWFd34ZTd4jguIMhmtl3e3HWvPItQOseG/E10FKCOeMRIf7in/61ei+DCF1y3csQZbZQPyoA8j/aT0+8AsLyVi0CM6cDox5zXgzcV9G/tLXUkeiw2z4IluMj2wD+tfOTdc+lADT6U3vTm4H0pncdaAF6n/61KPpxTeuOv4UD3xQB7l+x/n/hZep9f+QRL/6OhopP2P8A/kpep/8AYIl/9HQ0UAePDv39qPTP/wBekHv0pRx/hQAozyB9acKb/F6/SnDj60AKKltX8q4ikxnY6t9eai9P8mlUDpQB+hfhycXOgadMuNr28Z4Of4RWjXE/BjUG1L4a6FM5Jf7Oqkn1ArtqAOF+Llo114e2xgmTnaM96+dNB0a/1LUTp8ELCWaTajEfdNfTfj66jtdJMjlSY23BT3rnfA0NkdaW6ESqZE3p9aAM7wl8FNK0u8S91Nxd3Iw2CMgGvWYIY7eJYoEVI14CqMAVJRQAUUUzdmXaOg60APooo6DmgAqvfXS2luZX6Cs7Xtch0633KQzE4H1rzTxT4subkx28coAfgAetAHR6n4wLyfuflQErgfzrFXVbicFzIWLZG3NclDHci5wGyv3j6Gr8LvbW6ENly+cUAaEt0/khH3Es5XJPv+la0a3ltZ7g7ZIAX3FYcryQlJSAY+u2t7T72SKCKS6Uleg5oAy4bvWbTX9Ulv8AWTdWF4yNa2Pl7PsCrkYDZ+bIPPqcGum0zxUVmSCY4QY5x2rgfHOqxJ+5icLcE5BHaua/4SJormNZW4CjoaAPpqzu4rpA0bc9cVOyhhggH615n4L1P7XLDHHKSXIyQetd7r+pJpWly3UnbAX6mgCpqmn2eoRNGQhI9s14d8RPh5sn+0WUYC7uQveu/fxEqsJIpPmY5GT1NbsV1Bq8AikCFj1GehoA+OZ90EkkJXbNHJgccivWfgxKp8UXUBcCK5shuHphaw/i94PbSddubiNGWCTncvH1qx8JVaTXJIoWIkNkTuz07UAW9WzYpqjR4S0dCoUcfMGr0TwpdoNa8Ps5wXgA9jwa8/8AElrI+l3dtIrBwuBk4JPNdrpUPk634UiXhxCM/lQByX7UMSrolpIoOfteD/s5B/wr5tavpr9qLjw5CMdboY9uDXzK2PX2oAY1NHWnn8aYOtAAee9Hf0pT9aTPX+lAHuP7H/8AyUzU8/8AQIl/9HQ0Ufsff8lM1Mf9QiX/ANHQ0UAeOCnf5NIOe2c0v48CgBcfNz+NOHvTB+tO74zQA6lTr/LrTa0/DNidT8QabZD/AJbzqn4ZoA+z/gtpsml/DjQoJM7jbhz7Z7V3Wfl61S0i3W10yzhUALHCqDH0q2Dg88ZNAHBfFxvL0MT7sAZQD+8TXN+DZ5EWw67403HHf2rU+M8kcOhzRDeskjq20nKk+o9DjrjrXm8fi+LQDZQYaSeNB5xHWgD6PsZxNaxykEF+3pVquK8D+LrHxDaJ9kZRIMAj09q6/exkCgZGOuaAHlwNx9KpLdpJdbIj1wW54p8jhPNbAOBjnNZZeOEyS5ADnrQB0APrWX4i1KLTtPld25x0p1rqUElqzg/JEOvrXkPxD1uS4ee3jc/Mc5zQBna14hn1W+SG0U7F5yTXLCYLrG5yWZARt/w96sSSGzS3Nr8zgfNjrU0UES3X2naSzjkkdKAN6yjd7UO7YBGa09PtVm2E7iTjb6n3rMMgFqrSZC8Db/SrEWoyJfL5MeEhjwSKANfUo4o3GCCMAY7E1HczzQwj7QAYV5FZ8qPeeUSWVzkis7xNPdpZLbkkqD8xB60Acn4zuEhv3kmYfMMqRXNWAN7IsyuXUttC0vip7qW9SObJgKj5jW/8PvCV3d3kT2qhomYbBn+dAHrfwm0WX7Yt3nFvEv0y3at/4k6jia2sByhG+TH6f5966vQtPTStLit1ABUbnx3PevL9cvPt+pXdzN8jklUDHsOBQBgah5PnAW8mOCetZtn4kn0y43SElucIOdwHp/hUjoHZ0lPly5ypPesHXbVp/LcELNC25WJ6/SgD2HxHa2/i3wY8qgeeIuec4OK8p+DOlzz32oovF3DOIWGOkfWtL4V+KWttWGn3sriO4yuD/eq1LdJ4C8SeMtSJG64hBijHAZiMZ/WgDX8bpaX99bwWIyqTCNiB1IPrU2mEz/Eu0tIgT9khB6dOKl8MaT9jg0+O9Je5FsLqUnk7m5/rU3w8hlfxxrF/IhwUwhPcUAec/tRXzjTtNs3UAyTNJkdOP/1187Ma+gv2qpEx4fQY8w+c3Ttla+e29O9ACHp0pBwwxSnpwOKQfpQAUncjBPt0pT1P8qbnHBxQB7l+x7j/AIWXqX/YIl/9HQUUfsff8lM1PH/QIl/9HQ0UAeOjn6YpRz+HpSDHfpRQA4dfXmlHP16U0dfWnfrQA7tXY/B+3F18StBjYBh5pbB6cYrjhXe/AhVb4saArZwWf+QoA+3GXEWMdBjApuWBHGBjp708n5eaY/CqxYgDJI9aAPIvjdeJ9ssouu05IFfP+q3H/E5mJwxZ+T14r1L4gaidV8YLA7fugx56d686+IOhPo91DcRy+YsrZ+lAHcfAW+K+KrizDlWchlXOK+mowBweWHGT1r5S+BVvLeeNPtsAAEAAbjgZr6Gn8QRW8jxDO4sRj0OTn/GgDXuZFit/NIP7yTHHU57/AKVzPi64SG3NujgH73XPH+FM1/XM20KRr8quDWHq8hubwys3ygdume1AGityIPDjyCUHeM7s9ff6V414k1E3s5kEuxFcqTnrXR+NdWe00qCCNsCVioI9K84vcXlo4jZRtOTg96AOh03UbeVHQEyeX1bFak19bmyaKNlDqN/B5H1rl9DijjcxQkbH+8+O/wDhS3UTWNzPht0bgA89qAOu0Odp9Nie4+654GK6CxBuX2cDGAee1c1aSBrWFIj8iR5Xvg1r6SXtrNZZH/eHJ570AbF66RXS+WBhExkdM1ga5qdtI5aWRVIGCueat3M5SCW6f5wB04rkIdMn8S38c8geK1V9xAXr6YoA0F0hdYMK7AySEA44r3bwV4Yi0GxRdqh8dPSuQ8I6bDZ31pKc/Z06H6V6SL1nuQkaZj2Fi1AGV4m1yO1imtopNswXk+leXalMbiby2yroOGB61a8U6oby+lhbO9pC24dh6fpXPTzu8BYn96zbV9cUAWTPHIqpeIQQMK3TP41Qv4uDDKMjPyv7VoK8c8IWQHI47/zqjch0XZywPTnJxQBwfiASaTqEOoI2zypk5H1rtfjTZzalDZX8OR5NukkvOQ/Q1zXxFg/4kyqhJDzR9O5zXYePblwbXTI0/cz2aIzf3cgDFAHoFncpcPb3hxskslXgei9BVz4bqJ9MvLnC8yOFOOcVw3hy/aLSWsZR+8hgKKfbFdx8KoZo/BKJOD5hdu/OM0AfP/7UzyDxXpMLZMa2rMh+rDOK8SbmvZP2o7yKf4hwW8R/49bNUOPUnP8ASvGzQA3/ACaQdQe9L2pKAD6fSm564NOP04pvfmgD3L9j7/kpmp8f8wiX/wBHQ0Ufsff8lM1P/sES/wDo6GigDxzjuaUZ5zSdqB3xQA4fep3XHJ5pg7+lOHORQA8V1vwl1BdM+Jfh26kYBBciMnPTdxXIjoTxzT4JXinilicpJG4dGHUEUAfowjK6AjoRn8Kr3bD+z5mP8KE/pXKfC3xSnivwZp+oowabYI5lHVWHUV09ztm027VMOdjcevFAHy54gkN14jd1fBLsMjtXEagLwrM80rSpGx6nOBmu807TptZ1O7tbcA3Y3yBT16mqWgaTealql9YT2UkaIpExZehHfOOaAOr+HUcPh/Qkksvmvr8byO49K6TTLS7nYXFwTuUkms34R6KLvV9QuJtzRWq+RACOMV6vcWUNvaBFUfN1wKAOB1INDENwwJGwoqlcyC3XyXJLycqfQVs+IGja7QEBUTt71yfiK7V9xQHfjAIoA4fxvdtdXqqhLLB8q/X1rFkCJZSDOJHXgZ6tWhrUTwxJIgLSFsjnnNRG3t/I3XD7Xh+YjPUmgCrpjmO1gZyVAkw49a6W8ML+e6fNGcAE81zdjFBewohcB9zEr7DFbdwWtLE2hQmOUjLigCTQHna9kRsiHHyk10NxfAC2tlGVlOAetcXHfSvLLb2wYiFQNwPP8q7zR9Fnu7S0wmWVc7iD3oAm02zmvl5IEQOGWu3bQzY2VpbwJkXBxwOQKsaZ4QuIbW1BIQGQNJ7iuvMRTXreJUX7OsJI9sUAZNxpX2e8srSAE5XLH0qLxvqL+HNJRoAWeb92Mdq09KumvvEV8SPktx5Q+tO8Xab/AGjZwjy/MEb5xQB5CEEriVXV3K5x3B71QlBnvgEyDCOVx1re1XwxcxzM9kWjkzk9cGsn+z9QjkGYnEp6sB1+tAGfNdA9d6SoeNvQ/WlkuN6owxvHDeh47VujRZ7x9rQFGPGcY5q5qHhGW2s0YR4kH8XTFAHlnje4x9hiIJje5QfXmu98UwMps7pkytwm3nqOM1yuo6LPrvjfQ9E8ptsMnnu+OuO1eleJIYrzX9D0aAhngJ8xB1xg/pQByN3N/Z89jcOCEeNlYY71674KYt4Mt3YbXcMwA9M9a8y1+0GsaZrLWwytgWCkDuB2r1rwQBL4N0pmT5vIHHfNAHyP+0chj+JMik5P2WMk49z/AIV5Y3X9K9S/aQlMvxW1AH/lnBGvv3ry5uue9ADT0NJ3o5yRx7UnegBaTvSk8U09emKAPcv2Pv8Akpepf9giX/0dBRSfsfE/8LM1MY4/seXn/ttDRQB46OBRn8qbn3o7c/jQA4deaXP5/Smjrz19MUvfigB/X60oPPWmigce1AHqnwH8cz+FfFEenzMG0zUZAjqxx5ch6MPrX19abCzKh3RyLnNfBXgq1+3+L9FtiM+Zdpx9Oa+8NPTyGgQ5PyBPyoA+e9Qml8LeOBrtnGTHAziZMZ3DJr0fw54s0nxSzxaRaKtxfRZkYfw+ua43x/cRab4jkFyga3muvLkyMAA16D4P8KWvhydbjTEUQTKGUjsDz/WgDd0XRIdEthBar87HLH1q/fQMcEDPoK0FQFw2DnFPZN5G7tQB5lq9g63UhYEqa4PVg0EjMyEgHAHXNe83umRzB2xkt1rkdX8Lx7zvC46KD3oA+ftT8+41AlF4Vvu4pL61h2YJJYr8xr1W+8Jqjq0QGXOWx7Vnx+Djcy+SqhmdvmNAHklvEtmst3ISAfljT2rWOp3V1Cgit2kUgJwp4r1qL4dQSzBrgBgPlCV0Nj4Ngs0CLENoOfujFAHnfgXwM3m+ZMhLSkP9B6V7jomh21lbr8meMAGptGsEgQyED5hjGK1aAIbtV+zODwoHX0rlrzWmtWQRHdIVIDHn8a6e/J+zOoBO4Y47VzVrpiS6kIlDGBBw3cGgC74UtJoYmnlzmb5m9/St1pMSqmDyOtEMawxhIxhR0FUb7UIre6gRjnqWPoKALD2UL7t6DJ71CdJtWA3R5x0qSDULaZyscgJFWUkVxlTkUAUk02FD8sY49e9GpRJKqxmNmBB5A4GB3/pV7J2ggZNRsPMDbSVbp9aAOV0Lw9Baald6nMgMqghGPYY5rkPDCwXnjLXvEpk2xWls0XJwN1dv45v3sPDvlQj9/dOIFH+8ea4f4iwJ4e8LrpFiD5lzGTOy9/U/zoA5PwLfS/8ACu9Qmuzia9nk2g9WDEgV7f4dI07wrZmf5Uhtt7e2BmvBLy2LeHPCK2jYgS4AJH8Q96+grrT01DTZLdyVV4PKwCR1WgD4N+I+u/8ACR+NtY1UY8uaciMf7A4FcywrX8U6Y+jeINR06Q5ktrh0PGO+RWQaAG9aTuOlL27UnfpQAhznv2pO3bBpTSHr/SgD3L9j7/kpmp/9giX/ANHQ0Ufsff8AJTNT/wCwRL/6OhooA8azSV9u/wDCjvh3/wBC9/5O3H/xyj/hR3w7/wChe/8AJ25/+OUAfESDH0+tPyeOTX21/wAKO+Hf/Qvf+Ttx/wDHKP8AhR/w8/6F7/yduP8A45QB8TDr7e9KDz/hX2z/AMKP+Hn/AEL3/k7cf/HKP+FH/Dz/AKF7/wAnbj/45QB87fs76D/bfxEtpZFzFZKZSQeASMCvscRr5sbZ+7wPfvWB4S+H/hnwjcSz+HtMFpNKMO3nyyEj/gbGuoKKccdKAPnf46W4NxrG4jy3USZ9CK9X8F3B/wCEN0e5nYhBbDO76Vp694P0LX0kXVrH7QJBh/3rpn/vlhV610TT7XS49OgtytnGuxI/MY4HpknP60AcH4p+I1vpjFIWzIDhQD1rsvCepyanpEVxMDvbBrPm+HnheafzpdL3ycHcbiX/AOKro7Kyt7KBYbaIRxqMBQScfnQBJNNHDGXkYKo55rynxj46totT+yrOA2cYB/KvUbuxt7uMpcIzL6B2X+Rrkbr4V+Dru7NzcaS8k5OSxvJ+v/fdAGDoeqfbpSitvYAFq37U/Z5GCkBnPGfStfTPB+h6YzGysjGW6kzSNn82NX20awaVJDASy9D5jcfrQBTsLUiBpm5O7IyahdpxPgnAPat1beJE2KuF9MmozZW5IJQ59Q5/xoAmh/1S854p9NSNU+6MfjTsUANfGxt33cc5rOtbq3iLKrLk5xnj8DWhPCk8ZjkBKHqASP5VRXRbBWBELZHTMrn+tAGdq2uwxF44pRhRlmB6V5d4g8XF7hmikDbSQfpXrM/hfSJ2ZpbZyW4JE8g/k1Zg+HXhYEn+yzknP/HzL/8AFUAeSaP4wEFw0qXLFycEbulet+FdeS7h3SN0X16+9Vv+FV+DfML/ANj/ADZzn7VN1/77rd07wxpGnLts7VkX0M0jfzY0AX1uQSM9PUVJBKJFLL0pY7aKNdqqcehJNLFBHEMRqVH1NAGR4isor46a0y5WK5V8V5j47vPtXjPVoXIMdvbBME8DI617M0KMEDLkIcr7GsO98H6Fe3txeXNjvuZxiRxNIu78m4/CgDw3wuUk07QtPuHJSG7LJhckjsMdzX0XI/koWI+REJLemMdvz/Kufs/AnhyzmglttO2SQtvjbz5DtPry1dKyhlKsMgjBB70Afnb4vu3v/FOsXUpJeW7kJJ+uKxW6H0r7nuvgn8PrmeWafQN0srl3P224GSTkniSov+FF/Dk/8y7/AOT1z/8AHKAPhv8AnTTX3L/wor4c/wDQu/8Ak9c//HKP+FE/Dj/oXP8Ayeuf/jlAHw0f0pjHH0r7oPwK+HOP+Rd/8nrn/wCOUh+BPw4/6Fz/AMnrn/45QB4X+x7n/hZmp9f+QRL/AOjoaK+kfB3w08JeDdTl1Dw3pP2K8lhNu8n2maTKFlYjDuR1VecZ4ooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T1-weighted section shows that the large tumor in the previous image is invading the posteroapical chest wall (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2212=[""].join("\n");
var outline_f2_10_2212=null;
var title_f2_10_2213="Displaced tibial shaft fracture";
var content_f2_10_2213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Displaced tibial shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An anteroposterior (A)&nbsp;and lateral (B) radiograph of an unstable&nbsp;fracture of the tibial shaft are shown above.&nbsp;A fibular shaft fracture is also present. The tibial fracture&nbsp;was treated successfully with a locked reamed intramedullary nail (C and D). Yellow arrows indicate callus at the site of fracture healing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Petrisor BA, Bhandari M, Schemitsch E. Tibia and fibula fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Heckman JD, Court-Brown CM, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2213=[""].join("\n");
var outline_f2_10_2213=null;
var title_f2_10_2214="Development internal genitalia";
var content_f2_10_2214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Phenotypic differentiation of the female and male urogenital tracts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In females, the M&uuml;llerian ducts give rise to the fallopian tubes, uterus, and upper vagina, and the Wolffian ducts persist in vestigial form. In males, the Wolffian ducts give rise to the epididymides, vasa deferentia, seminal vesicles, and ejaculatory ducts, and the M&uuml;llerian ducts regress.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2214=[""].join("\n");
var outline_f2_10_2214=null;
var title_f2_10_2215="Overview of overuse (chronic) tendinopathy";
var content_f2_10_2215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of overuse (chronic) tendinopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2215/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2215/contributors\">",
"     Karim Khan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2215/contributors\">",
"     Alex Scott, PhD, RPT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2215/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2215/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2215/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2215/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/10/2215/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H32168046\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendinopathy is a clinical syndrome characterized by tendon thickening and chronic, localized tendon pain. It may result from acute trauma (eg, tendon laceration or rupture) or more commonly, from overuse. Recovery from acute tendinopathy follows more or less well-established treatment protocols, which are discussed in reviews of specific injuries.",
"   </p>",
"   <p>",
"    Historically, overuse tendinopathy was commonly referred to as tendinitis. The &ldquo;-itis&rdquo; suffix implicated inflammation as the primary cause of pain and swelling. In fact, a classic inflammatory reaction is typically absent with overuse tendinopathy, or only minimally present in adjacent peritendinous or bursal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/1\">",
"     1",
"    </a>",
"    ]. The pathophysiology underlying most cases, as judged by tissue analysis from a variety of commonly affected tendons, is tendinosis.",
"    <strong>",
"    </strong>",
"    Tendinosis may be broadly characterized as a failed healing response within the tendon tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/2\">",
"     2",
"    </a>",
"    ]. This failed healing response is associated with characteristic findings on ultrasound and MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the clinically relevant aspects of the pathophysiology of overuse tendinopathy. The diagnosis and management of overuse tendinopathy generally and in specific tendons is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32537?source=see_link\">",
"     \"Achilles tendinopathy and tendon rupture\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=see_link\">",
"     \"Epicondylitis (tennis and golf elbow)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32168053\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND TERMINOLOGY: TENDINOSIS VERSUS TENDINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our knowledge of the pathophysiology of overuse tendinopathy stems mainly from surgical biopsies taken from athletes with chronic tendon pain who have failed conservative treatment and undergone open or arthroscopic tendon debridement. Numerous histopathology and gene array studies have been performed on these tissue specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/4-17\">",
"     4-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathology of a wide variety of tendons examined in this manner consistently reveals an absence, or very minimal presence, of inflammatory cells. This is true of the Achilles, posterior tibial, patellar, gluteal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/18\">",
"     18",
"    </a>",
"    ], adductor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/19\">",
"     19",
"    </a>",
"    ], extensor carpi radialis brevis and longus, flexor carpi ulnaris, flexor digitorum [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/20\">",
"     20",
"    </a>",
"    ], and rotator cuff tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/6,11,17,21,22\">",
"     6,11,17,21,22",
"    </a>",
"    ]. Gene array studies generally confirm the absence of inflammatory gene upregulation in tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/13,23\">",
"     13,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical inflammatory response does occur in tendons following vascular disruption, whether from microscopic, partial, or complete rupture of the tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, these responses are not sufficiently long-lasting or widespread to explain the chronic symptoms of tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/27\">",
"     27",
"    </a>",
"    ]. Nevertheless, increased COX-2 expression indicates that there may be a mild low-grade inflammation even in longstanding cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of inflammation in acute paratendonitis (eg, DeQuervain's tenosynovitis) may be more prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/16\">",
"     16",
"    </a>",
"    ]. However, in the chronic stage, DeQuervain&rsquo;s tenosynovitis is also characterized by a lack of inflammation and widespread degenerative changes affecting the sheath and the tendon itself.",
"   </p>",
"   <p>",
"    Instead of inflammation, overuse tendinopathy is characterized by chronic degenerative changes in tendon structure that reflect scarring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a failed healing response. The histology and imaging studies of involved tendons demonstrate characteristic changes in appearance. Tendinosis is the term used to describe this condition.",
"   </p>",
"   <p>",
"    The attached table and figures describe normal tendon appearance and the major pathological changes of tendinosis in presumed chronological order (",
"    <a class=\"graphic graphic_table graphicRef78153 \" href=\"UTD.htm?0/21/348\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65364 \" href=\"UTD.htm?3/62/4073\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73812 \" href=\"UTD.htm?36/63/37879\">",
"     picture 1",
"    </a>",
"    ). These abnormal features include abnormalities of the tendon fibroblasts and extracellular matrix, collagen degeneration and accelerated turnover, and",
"    <span class=\"nowrap\">",
"     neovascularization/angiogenesis.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32168060\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased participation in recreational sporting activity, particularly among middle-aged and elder adults, has led to an increasing incidence of overuse tendinopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/29\">",
"     29",
"    </a>",
"    ]. Risk factors for tendinopathy are often divided into intrinsic factors (pertaining to the properties of an individual's tendon or healing capacity) and extrinsic factors (pertaining to the load placed on the tendon; eg, the volume of exercise) (",
"    <a class=\"graphic graphic_table graphicRef55764 \" href=\"UTD.htm?9/18/9515\">",
"     table 2",
"    </a>",
"    ). Among these many factors, advancing age (intrinsic) and increased overall volume of tendon load (extrinsic) pose the greatest risk for developing overuse tendinopathy.",
"   </p>",
"   <p>",
"    Age over 35 years is associated with an increased incidence of many overuse tendinopathies, including Achilles tendinopathy in runners and rotator cuff tendinopathy in throwing athletes or manual laborers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/29\">",
"     29",
"    </a>",
"    ]. As tendons age, collagen turnover slows and cross-links accumulate between collagen fibrils, resulting in a stiffer muscle tendon unit and reduced energy absorbing capacity, which may predispose to injury [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In addition, age may reduce the tendon's capacity to repair the ongoing microtrauma that occurs during tendon loading activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast, young athletes are more prone to injury at tendon and ligament insertions (biomechanical weak points) than in the midportion of the tendon. Thus, enthesopathies such as Osgood-Schlatter's disease and calcaneal apophysitis are more common in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and management of heel pain in the young athlete\", section on 'Calcaneal apophysitis (Sever disease)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gender strongly influences the risk of developing certain tendinopathies. As an example, patellar tendinopathy is five times more common in male than female jumping athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/33\">",
"     33",
"    </a>",
"    ]. The influence of gender on tendinopathy is incompletely understood but may represent a combination of biomechanical variables (eg, hip to knee angles), hormonal influences (eg, estrogen levels and menopausal status), and different sporting or occupational behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biomechanical abnormalities are associated with an increased risk of tendinopathy, particularly in the lower extremity. Thus, if abnormal postures or movements are noted in patients with chronic tendon pain, a complete biomechanical assessment by a physiotherapist or other clinician with comparable expertise should be performed. Pes planus (flat foot) or pes cavus (high arched foot), subtalar joint stiffness, reduced ankle dorsiflexion, muscle tightness, and sacroiliac joint dysfunction have all been reported to play a role in the development of tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Increased thoracic kyphosis may predispose the rotator cuff to repetitive impingement against the overlying acromial arch due to scapular protraction and reduction of the subacromial space [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior tendon lesions represent a significant risk factor for developing tendinopathy. In high-risk groups, such as athletes participating in jumping sports with a high prevalence of patellar or Achilles tendinopathy, asymptomatic lesions identified on ultrasound at the start of an athletic season are associated with an increased risk of developing a symptomatic tendinopathy during the season [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tendinopathies often develop bilaterally or at multiple locations in the same individual. Some progress has been made in exploring the role of the genetics and the heritability of overuse tendinopathies, and this research may eventually lead to the identification of high-risk individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/42\">",
"     42",
"    </a>",
"    ]. A single nucleotide polymorphism associated with reduced levels of GDF-5 (growth and differentiation factor 5, important for tendon development and healing) is associated with twice the risk of developing Achilles tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extrinsic risk factors for overuse tendinopathy include training errors (eg, sudden increase in tendon loading activity, inadequate rest), poor environmental conditions (eg, cambered road surfaces, hard gym floors, frozen turf, extreme temperatures, poor ergonomics), and inadequate equipment (eg, old or inappropriate footwear) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/29,44-47\">",
"     29,44-47",
"    </a>",
"    ]. Of these, sudden substantial increases in training load without adequate time for the body to adjust (eg, doubling of cumulative running distances from one week to the next) incur the greatest risk.",
"   </p>",
"   <p>",
"    Suboptimal ergonomics play a role in the development of many upper extremity tendinopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/44\">",
"     44",
"    </a>",
"    ]. Excessive movement or awkward hand, wrist, and shoulder postures during daily or occupational activities can strain tendons.",
"   </p>",
"   <p>",
"    Fluoroquinolone use is associated with increased risk of tendinopathy and tendon rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. However, the mechanism has not yet been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H29#H29\">",
"     \"Fluoroquinolones\", section on 'Tendinopathy and tendon rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32168067\">",
"    <span class=\"h1\">",
"     MAJOR CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical features associated with tendinopathy are pain with palpation of the affected part of the tendon(s) and pain with tendon loading. Superficial tendinopathies, such as the Achilles, demonstrate observable tendon thickening. In nonsuperficial tendons, thickening may not be apparent, but is often clinically significant, as in the case of the rotator cuff where thickening exacerbates the impingement involving a narrow subacromial space. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It can be difficult to distinguish clinically between chronic paratendonitis and tendinosis. In cases of acute paratendonitis (inflammation in tissues adjacent to the tendon), crepitus or fluid in the tendon lining may be palpable. However, the distinction between chronic paratendonitis and tendinosis is often unimportant because clinical management is unchanged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although pathology may exist within the tendon or its associated structures, it is important to note that the underlying cause of tendinopathy may lie elsewhere. A thorough assessment performed by a clinician knowledgeable about musculoskeletal evaluation often reveals changes elsewhere in the kinetic chain, including muscle weakness, abnormal movement patterns, or joint stiffness. In addition, tendinopathy, like other pain syndromes, may involve referred pain, muscle spasm or tenderness, or other regional (or even contralateral) motor abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3248426\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic changes in tendon appearance on ultrasound or magnetic resonance imaging (MRI) studies can be used to confirm the diagnosis of tendinosis, identify macroscopic tears (which may be amenable to surgical repair), and determine the extent of involvement of associated structures (eg, presence of bony spurs or fragments, labral lesions, bursal pathology).",
"   </p>",
"   <p>",
"    Grey scale or color Doppler ultrasound are particularly useful for detecting tendon pathology, and may reveal tendon thickening, hypoechoic areas, and increased blood flow (neovascularization) in the deep portions of the tendon. There is a moderate association between the presence of neovascularization and patients&rsquo; symptoms and functional limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/53\">",
"     53",
"    </a>",
"    ]. MRI reveals increased signal in abnormal tendons, corresponding to the increased water content associated with excessive proteoglycans and increased blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32168074\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with overuse tendinopathy present in the chronic stage (over three months of symptoms). Once present, tendinopathies may be refractory to treatment and some become career limiting for professional athletes.",
"   </p>",
"   <p>",
"    As an example, one randomized trial clearly describes the recalcitrant nature of chronic Achilles tendinopathy, in which there was slow, but gradual improvement in the average load-induced pain score from",
"    <span class=\"nowrap\">",
"     7.9/10",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     5.9/10",
"    </span>",
"    over the course of four months in untreated patients with at least three month symptom duration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/54\">",
"     54",
"    </a>",
"    ]. However, beyond four months, only 24 percent of untreated patients reported significant improvement or cure. These rates are slightly worse than those reported in another randomized trial of patients with lateral &ldquo;epicondylitis&rdquo; of at least six weeks duration, where after three months without treatment 42 percent of patients reported significant improvement in day-time pain without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/55\">",
"     55",
"    </a>",
"    ]. In both studies, patients treated with physiotherapy that emphasized active exercise (ie, eccentric training) experienced significantly higher improvement rates than those treated with alternative approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/56\">",
"     56",
"    </a>",
"    ]. Treatment of chronic tendinopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Debate continues about the extent to which tendinopathy is reversible, as determined by histology or imaging. Longitudinal studies have reported a reduction in ultrasound abnormalities in successfully treated tendons, including normalization of tendon thickness and reduction of hypoechoic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2215/abstract/57\">",
"     57",
"    </a>",
"    ]. However, considerable symptomatic improvement and successful return to activity is seen in some patients with persistent, macroscopically apparent pathology who follow a proper rehabilitation program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3248447\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tendinopathy is a clinical syndrome characterized by tendon thickening and chronic, localized tendon pain. Tendon overuse is a leading cause.",
"     </li>",
"     <li>",
"      Overuse tendinopathy is characterized by chronic degenerative changes in tendon structure that reflect scarring",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a failed healing response. (See",
"      <a class=\"local\" href=\"#H32168053\">",
"       'Pathology and terminology: tendinosis versus tendinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A classic cellular inflammatory reaction is typically absent with overuse tendinopathy, or only minimally present in adjacent peritendinous or bursal tissue.",
"     </li>",
"     <li>",
"      Risk factors for tendinopathy are often divided into intrinsic factors (pertaining to the properties of an individual's tendon or healing capacity) and extrinsic factors (pertaining to the load placed on the tendon). Among many risk factors, advancing age and increased overall volume of tendon load pose the greatest risk for developing overuse tendinopathy. (See",
"      <a class=\"local\" href=\"#H32168060\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical features associated with tendinopathy are pain with palpation of the affected part of the tendon and pain with tendon loading. (See",
"      <a class=\"local\" href=\"#H32168067\">",
"       'Major clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overuse tendinopathy manifests characteristic findings on imaging studies using MRI or ultrasound. (See",
"      <a class=\"local\" href=\"#H3248426\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/1\">",
"      Khan KM, Cook JL, Bonar F, et al. Histopathology of common tendinopathies. Update and implications for clinical management. Sports Med 1999; 27:393.",
"     </a>",
"    </li>",
"    <li>",
"     Nirschl, RP. Patterns of failed hearing in tendon injury. In: Sports-Induced Inflammation: Clinical and Basic Science Concepts, Leadbetter, WB, Buckwalter, JA, Gordon, SL (Eds), American Academy of Orthopaedic Surgeons, Park Ridge 1990. p.577.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/3\">",
"      Cook JL, Khan KM, Kiss ZS, Griffiths L. Patellar tendinopathy in junior basketball players: a controlled clinical and ultrasonographic study of 268 patellar tendons in players aged 14-18 years. Scand J Med Sci Sports 2000; 10:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/4\">",
"      Khan KM, Bonar F, Desmond PM, et al. Patellar tendinosis (jumper's knee): findings at histopathologic examination, US, and MR imaging. Victorian Institute of Sport Tendon Study Group. Radiology 1996; 200:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/5\">",
"      Chard MD, Cawston TE, Riley GP, et al. Rotator cuff degeneration and lateral epicondylitis: a comparative histological study. Ann Rheum Dis 1994; 53:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/6\">",
"      Galliani I, Burattini S, Mariani AR, et al. Morpho-functional changes in human tendon tissue. Eur J Histochem 2002; 46:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/7\">",
"      J&auml;rvinen M, J&oacute;zsa L, Kannus P, et al. Histopathological findings in chronic tendon disorders. Scand J Med Sci Sports 1997; 7:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/8\">",
"      Rolf CG, Fu BS, Pau A, et al. Increased cell proliferation and associated expression of PDGFRbeta causing hypercellularity in patellar tendinosis. Rheumatology (Oxford) 2001; 40:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/9\">",
"      Kvist M, J&oacute;zsa L, J&auml;rvinen MJ, Kvist H. Chronic Achilles paratenonitis in athletes: a histological and histochemical study. Pathology 1987; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/10\">",
"      Martens M, Wouters P, Burssens A, Mulier JC. Patellar tendinitis: pathology and results of treatment. Acta Orthop Scand 1982; 53:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/11\">",
"      Mosier SM, Pomeroy G, Manoli A 2nd. Pathoanatomy and etiology of posterior tibial tendon dysfunction. Clin Orthop Relat Res 1999; :12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/12\">",
"      Popp JE, Yu JS, Kaeding CC. Recalcitrant patellar tendinitis. Magnetic resonance imaging, histologic evaluation, and surgical treatment. Am J Sports Med 1997; 25:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/13\">",
"      Ireland D, Harrall R, Curry V, et al. Multiple changes in gene expression in chronic human Achilles tendinopathy. Matrix Biol 2001; 20:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/14\">",
"      Riley GP, Harrall RL, Constant CR, et al. Glycosaminoglycans of human rotator cuff tendons: changes with age and in chronic rotator cuff tendinitis. Ann Rheum Dis 1994; 53:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/15\">",
"      Movin T, Gad A, Reinholt FP, Rolf C. Tendon pathology in long-standing achillodynia. Biopsy findings in 40 patients. Acta Orthop Scand 1997; 68:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/16\">",
"      Clarke MT, Lyall HA, Grant JW, Matthewson MH. The histopathology of de Quervain's disease. J Hand Surg Br 1998; 23:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/17\">",
"      Sarkar K, Uhthoff HK. Ultrastructure of the common extensor tendon in tennis elbow. Virchows Arch A Pathol Anat Histol 1980; 386:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/18\">",
"      Fearon AM, Scarvell JM, Cook JL, Smith PN. Does ultrasound correlate with surgical or histologic findings in greater trochanteric pain syndrome? A pilot study. Clin Orthop Relat Res 2010; 468:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/19\">",
"      Weinstein RN, Kraushaar BS, Fulkerson JP. Adductor tendinosis in a professional hockey player. Orthopedics 1998; 21:809.",
"     </a>",
"    </li>",
"    <li>",
"     Lundin A. \"Trigger finger is a form of tendinosis\". Presented at: International Scientific Tendinopathy Symposium. Umea, Sweden. 30 September 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/21\">",
"      Budoff JE, Kraushaar BS, Ayala G. Flexor carpi ulnaris tendinopathy. J Hand Surg Am 2005; 30:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/22\">",
"      Maffulli N, Testa V, Capasso G, et al. Similar histopathological picture in males with Achilles and patellar tendinopathy. Med Sci Sports Exerc 2004; 36:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/23\">",
"      Alfredson H, Lorentzon M, B&auml;ckman S, et al. cDNA-arrays and real-time quantitative PCR techniques in the investigation of chronic Achilles tendinosis. J Orthop Res 2003; 21:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/24\">",
"      Premdas J, Tang JB, Warner JP, et al. The presence of smooth muscle actin in fibroblasts in the torn human rotator cuff. J Orthop Res 2001; 19:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/25\">",
"      ARNER O, LINDHOLM A, ORELL SR. Histologic changes in subcutaneous rupture of the Achilles tendon; a study of 74 cases. Acta Chir Scand 1959; 116:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/26\">",
"      Svensson M, Kartus J, Christensen LR, et al. A long-term serial histological evaluation of the patellar tendon in humans after harvesting its central third. Knee Surg Sports Traumatol Arthrosc 2005; 13:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/27\">",
"      Khan KM, Cook JL, Maffulli N, Kannus P. Where is the pain coming from in tendinopathy? It may be biochemical, not only structural, in origin. Br J Sports Med 2000; 34:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/28\">",
"      Legerlotz K, Jones ER, Screen HR, Riley GP. Increased expression of IL-6 family members in tendon pathology. Rheumatology (Oxford) 2012; 51:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/29\">",
"      Maffulli N, Wong J, Almekinders LC. Types and epidemiology of tendinopathy. Clin Sports Med 2003; 22:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/30\">",
"      Woo SL, Ritter MA, Amiel D, et al. The biomechanical and biochemical properties of swine tendons--long term effects of exercise on the digital extensors. Connect Tissue Res 1980; 7:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/31\">",
"      O'Brien M. Structure and metabolism of tendons. Scand J Med Sci Sports 1997; 7:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/32\">",
"      Schechtman H, Bader DL. Fatigue damage of human tendons. J Biomech 2002; 35:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/33\">",
"      Ferretti A. Epidemiology of jumper's knee. Sports Med 1986; 3:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/34\">",
"      Kjaer M, Hansen M. The mystery of female connective tissue. J Appl Physiol 2008; 105:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/35\">",
"      Kaufman KR, Brodine SK, Shaffer RA, et al. The effect of foot structure and range of motion on musculoskeletal overuse injuries. Am J Sports Med 1999; 27:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/36\">",
"      Kvist M. Achilles tendon injuries in athletes. Ann Chir Gynaecol 1991; 80:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/37\">",
"      Witvrouw E, Bellemans J, Lysens R, et al. Intrinsic risk factors for the development of patellar tendinitis in an athletic population. A two-year prospective study. Am J Sports Med 2001; 29:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/38\">",
"      Voorn R. Case report: can sacroiliac joint dysfunction cause chronic Achilles tendinitis? J Orthop Sports Phys Ther 1998; 27:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/39\">",
"      Lewis JS, Green A, Wright C. Subacromial impingement syndrome: the role of posture and muscle imbalance. J Shoulder Elbow Surg 2005; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/40\">",
"      Khan KM, Cook JL, Kiss ZS, et al. Patellar tendon ultrasonography and jumper's knee in female basketball players: a longitudinal study. Clin J Sport Med 1997; 7:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/41\">",
"      Cook JL, Khan KM, Kiss ZS, et al. Prospective imaging study of asymptomatic patellar tendinopathy in elite junior basketball players. J Ultrasound Med 2000; 19:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/42\">",
"      Mokone GG, Schwellnus MP, Noakes TD, Collins M. The COL5A1 gene and Achilles tendon pathology. Scand J Med Sci Sports 2006; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/43\">",
"      Posthumus M, Collins M, Cook J, et al. Components of the transforming growth factor-beta family and the pathogenesis of human Achilles tendon pathology--a genetic association study. Rheumatology (Oxford) 2010; 49:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/44\">",
"      Werner RA, Franzblau A, Gell N, et al. Predictors of persistent elbow tendonitis among auto assembly workers. J Occup Rehabil 2005; 15:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/45\">",
"      J&auml;rvinen TA, Kannus P, Maffulli N, Khan KM. Achilles tendon disorders: etiology and epidemiology. Foot Ankle Clin 2005; 10:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/46\">",
"      Soslowsky LJ, Carpenter JE, DeBano CM, et al. Development and use of an animal model for investigations on rotator cuff disease. J Shoulder Elbow Surg 1996; 5:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/47\">",
"      Renstr&ouml;m P, Johnson RJ. Overuse injuries in sports. A review. Sports Med 1985; 2:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/48\">",
"      Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/49\">",
"      Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/50\">",
"      Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001; 75:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/51\">",
"      van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001; 45:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/52\">",
"      Fern&aacute;ndez-Carnero J, Fern&aacute;ndez-de-las-Pe&ntilde;as C, de la Llave-Rinc&oacute;n AI, et al. Bilateral myofascial trigger points in the forearm muscles in patients with chronic unilateral lateral epicondylalgia: a blinded, controlled study. Clin J Pain 2008; 24:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/53\">",
"      Cook JL, Malliaras P, De Luca J, et al. Neovascularization and pain in abnormal patellar tendons of active jumping athletes. Clin J Sport Med 2004; 14:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/54\">",
"      Rompe JD, Nafe B, Furia JP, Maffulli N. Eccentric loading, shock-wave treatment, or a wait-and-see policy for tendinopathy of the main body of tendo Achillis: a randomized controlled trial. Am J Sports Med 2007; 35:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/55\">",
"      Smidt N, van der Windt DA, Assendelft WJ, et al. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. Lancet 2002; 359:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/56\">",
"      N&oslash;rregaard J, Larsen CC, Bieler T, Langberg H. Eccentric exercise in treatment of Achilles tendinopathy. Scand J Med Sci Sports 2007; 17:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2215/abstract/57\">",
"      Ohberg L, Lorentzon R, Alfredson H. Eccentric training in patients with chronic Achilles tendinosis: normalised tendon structure and decreased thickness at follow up. Br J Sports Med 2004; 38:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13803 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2215=[""].join("\n");
var outline_f2_10_2215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3248447\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32168046\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32168053\">",
"      PATHOLOGY AND TERMINOLOGY: TENDINOSIS VERSUS TENDINITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32168060\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32168067\">",
"      MAJOR CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3248426\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32168074\">",
"      NATURAL HISTORY AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3248447\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13803|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/62/4073\" title=\"figure 1\">",
"      Tendinosis pathology summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13803|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/63/37879\" title=\"picture 1\">",
"      Histopathology of tendinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/21/348\" title=\"table 1\">",
"      Histopathological classification of tendon disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/18/9515\" title=\"table 2\">",
"      Clinical risk factors for overuse tendinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32537?source=related_link\">",
"      Achilles tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=related_link\">",
"      Clinical features and management of heel pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1354?source=related_link\">",
"      Epicondylitis (tennis and golf elbow)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=related_link\">",
"      Overview of the management of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_10_2216="Azathioprine: Pediatric drug information";
var content_f2_10_2216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azathioprine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"    see \"Azathioprine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/31/28149?source=see_link\">",
"    see \"Azathioprine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azasan&reg;;",
"     </li>",
"     <li>",
"      Imuran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Azathioprine&reg;;",
"     </li>",
"     <li>",
"      Imuran&reg;;",
"     </li>",
"     <li>",
"      Mylan-Azathioprine;",
"     </li>",
"     <li>",
"      Teva-Azathioprine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      see \"Azathioprine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with intermediate TPMT activity may be at risk for increased myelosuppression; those with low or absent TPMT activity receiving conventional azathioprine doses are at risk for developing severe, life-threatening myelotoxicity. Dosage reductions are recommended for patients with reduced TPMT activity.",
"     <b>",
"      Note:",
"     </b>",
"     I.V. dose is equivalent to oral dose (dosing should be transitioned from I.V. to oral as soon as tolerated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hepatitis, autoimmune:",
"     </b>",
"     Limited data available: Children and Adolescents: Oral: Initial: 0.5 mg/kg/dose once daily; titrate as needed up to 2 mg/kg/dose once daily; for long-term therapy, a low-dose of 1-1.5 mg/kg/day may be effective in some patients (Della Corte, 2012; Vitfell-Pedersen, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Immune (idiopathic) thrombocytopenic purpura, chronic refractory:",
"     </b>",
"     Limited data available: Children &ge;2 years and Adolescents: Oral: Maintenance: 2-2.5 mg/kg/day, rounded to the nearest 50 mg (Boruchov, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Inflammatory bowel disease:",
"     </b>",
"     Limited data available: I.V., Oral: 2-2.5 mg/kg/dose once daily; titrate to effect; usual reported range: 1-3 mg/kg/dose once daily; reported maximum daily dose: 4 mg/kg/day or 200 mg/day; may takes several weeks of therapy to be fully effective (Fuentes, 2003; Punati, 2011; Riello, 2011; Sandhu, 2010). Some data suggest that pediatric patients &le;6 years may require higher doses to achieve remission; a median dose of 3.51 mg/kg/day (maximum daily dose: 5 mg/kg/day) was reported to induce remission in 62% of patients &le;6 years of age vs 17% of those receiving lower doses (ie, &lt;2-3 mg/kg/day study group; median dose: 2.46 mg/kg/day) (Grossman, 2008). Intravenous administration of 3 mg/kg/day  for 5 days has  been used for refractory IBD in a retrospective trial of 115 pediatric patients (1-17 years) to initiate azathioprine therapy and then switched to oral therapy at the same dose (Fuentes, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Juvenile-idiopathic arthritis (rheumatoid arthritis):",
"     </b>",
"     Limited data available: Children and Adolescents: Oral: 2-2.5 mg/kg/dose once daily; data limited to single double-blind, placebo-controlled trial of pediatric patients (n=17 treatment group); efficacy results were not statistically significant (response rate: Treatment:  41% vs placebo: 27%); data suggested a minimum trial of 12 weeks to fully assess therapeutic response (AHRQ, 2011; Hashkes, 2005; Kvien, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Lupus nephritis, mild:",
"     </b>",
"     Limited data available: Children and Adolescents: Oral: 2-2.5 mg/kg/dose once daily (Bertsias, 2012; Marks, 2010);",
"     <b>",
"      Note:",
"     </b>",
"     Some data suggest less effective in non-Caucasian pediatric patients; some centers recommend use for primary induction in Caucasian patients with less severe disease (Adams, 2006; Marks, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Myasthenia gravis, juvenile:",
"     </b>",
"     Limited data available: Children and Adolescents: Oral: 1-3 mg/kg/dose once daily (Ashraf, 2006; Lindner, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Transplantation, solid organ:",
"     </b>",
"     Limited data available: Oral, I.V.: Initial: 3-5 mg/kg/dose once daily, beginning at the time of transplant; maintenance: 1-3 mg/kg/dose once daily (Denfield, 2010; Ford, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Uveitis, JIA-associated:",
"     </b>",
"     Limited data available: Children and Adolescents: Initial: 2.4 mg/kg/dose once daily; reported range: 1.4-3.2 mg/kg/dose once daily; in a retrospective review of 41 children, a maintenance 2.1 mg/kg/dose (range: 1-2.8 mg/kg/dose) once daily was reported as monotherapy and/or in combination with other immunosuppressive agents; infectious etiology was excluded; the authors recommend doses of &lt;3 mg/kg/day (Goebel, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Renal transplantation (treatment usually started the day of transplant; however, has been initiated [rarely] 1-3 days prior to transplant):",
"     </b>",
"     Oral, I.V.: Initial: 3-5 mg/kg/day usually given as a single daily dose, then maintenance 1-3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: 1 mg/kg/day (50-100 mg) given once daily or divided twice daily for 6-8 weeks; may increase by 0.5 mg/kg every 4 weeks until response or up to a maximum daily dose of 2.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; an adequate trial should be a minimum of 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose: Reduce dose by 0.5 mg/kg (~25 mg daily) every 4 weeks until lowest effective dose is reached; optimum duration of therapy not specified; may be discontinued abruptly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant use with allopurinol:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: Limited data available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Reduce azathioprine dose to 25% to 33% of the usual dose when used concurrently with allopurinol. Patients with low or absent TPMT activity may require further dose reductions or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: Limited data available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Rapid WBC count decrease, persistently low WBC count, or serious infection: Reduce dose or temporarily withhold treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe toxicity in renal transplantation: May require discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease): Permanently discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of dose once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of dose once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis (dialyzable; ~45% removed in 8 hours): Administer 50% of normal dose once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CAPD: Administer 50% of normal dose once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CRRT: Administer 75% of normal dose once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Although dosage reductions are recommended, specific guidelines are not available in the manufacturer&rsquo;s labeling; the following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis (dialyzable; ~45% removed in 8 hours): Administer supplement: 0.25 mg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CAPD: Unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CRRT: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azasan&reg;: 75 mg, 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imuran&reg;: 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food or may administer in divided doses to decrease GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Reconstitute vial with 10 mL SWI; administer IVP over 5 minutes at a concentration not to exceed 10 mg/mL; or may be further diluted with NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     W and administered by intermittent infusion over 30-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F138269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS. Stable in neutral or acid solutions, but is hydrolyzed to mercaptopurine in alkaline solutions.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Azasan&reg;: Store at 20&ordm; to 25&ordm; C (68&ordm; to 77&ordm; F); protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Imuran&reg;: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for injection: Store intact vials at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from light and retain in original carton until ready for use. Reconstituted solution should be used within 24 hours; solutions further diluted with D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, or NS for infusion are stable at room temperature or refrigerated for up to 16 days (Johnson, 1981); however, the manufacturer recommends use within 24 hours of reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct with other agents in prevention of kidney transplant rejection (FDA approved in adults); management of active rheumatoid arthritis (FDA approved in adults); has also been used as an immunosuppressant in a variety of autoimmune diseases such as SLE, juvenile idiopathic arthritis (JIA), JIA-associated uveitis, myasthenia gravis, and autoimmune hepatitis, and as a steroid-sparing agent for corticosteroid-dependent inflammatory bowel disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AzaTHIOprine may be confused with azaCITIDine, azidothymidine, azithromycin, Azulfidine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Imuran&reg; may be confused with Elmiron&reg;, Enduron, Imdur&reg;, Inderal&reg;, Tenormin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Azathioprine is metabolized to mercaptopurine; concurrent use of these commercially-available products has resulted in profound myelosuppression.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, nausea/vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubin increased, hepatotoxicity, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Infection (includes bacterial, fungal, protozoal, viral); neoplasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Abdominal pain, alopecia, anemia, arthralgia, bleeding, bone marrow suppression, fever, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease), hepatosplenic T-cell lymphoma, hypersensitivity, hypotension, interstitial pneumonitis, lymphoma, macrocytic anemia, negative nitrogen balance, pancreatitis, pancytopenia, rash, skin cancer, steatorrhea, Sweet&rsquo;s syndrome (acute febrile neutrophilic dermatosis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azathioprine or any component; pregnancy (patients with rheumatoid arthritis); patients with rheumatoid arthritis previously treated with alkylating agents (eg, cyclophosphamide, chlorambucil, melphalan) may have a prohibitive risk of neoplasia with azathioprine treatment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in renal impairment (relative oliguria) and those with cadaveric kidney transplants with tubular necrosis in the immediate transplant period; dosage modification may be necessary due to decreased clearance.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with hepatic impairment; discontinue azathioprine therapy in patients with hepatic sinusoidal obstruction syndrome [SOS; formerly called veno-occlusive disease (VOD)]. Hepatotoxicity (transaminase, bilirubin, and alkaline phosphatase elevations) may occur, usually in renal transplant patients and generally within 6 months of transplant; normally reversible with discontinuation; monitor liver function periodically. Should be prescribed by physicians familiar with the risks, including hematologic toxicities and mutagenic potential",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Immunosuppressive agents, including azathioprine, are associated with the development of lymphoma and other malignancies",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , especially of the skin. Hepatosplenic T-cell lymphoma (HSTCL), a rare white blood cell cancer that is usually fatal, has predominantly occurred in adolescents and young adults treated for Crohn's disease or ulcerative colitis and receiving TNF blockers (eg, adalimumab, certolizumab pegol, etanercept, golimumab), azathioprine, and/or mercaptopurine. Most cases have occurred in patients treated with a combination of immunosuppressant agents, although there have been reports of HSTCL in patients receiving azathioprine or mercaptopurine monotherapy. Renal transplant patients are also at increased risk for malignancy (eg, skin cancer, lymphoma); limit sun and ultraviolet light exposure and use appropriate sun protection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dose-related hematologic toxicities (leukopenia, thrombocytopenia, anemias, including macrocytic anemia or pancytopenia) may occur; delayed toxicities may also occur; may be more severe with renal transplants undergoing rejection and in patients with genetic deficiency of thiopurine methyltransferase (TPMT). Patients with intermediate TPMT activity may be at risk for increased myelosuppression; those with low or absent TPMT activity are at risk for developing severe and life-threatening hematologic toxicity. TPMT genotyping or phenotyping may assist in identifying patients at risk for developing toxicity. Monitor hematologic function closely; may require dosage reduction or temporary discontinuation of azathioprine if there is a rapid decrease or persistently low leukocyte counts. Patients on concurrent therapy with drugs which may inhibit TPMT (eg, olsalazine) or xanthine oxidase (eg, allopurinol) may be at higher risk for myelosuppressive effects. Reduced dosage of azathioprine may be recommended when used concurrently with allopurinol; patients with low or absent TPMT activity may require further dose reductions or discontinuation. Azathioprine is metabolized to mercaptopurine; concomitant use may result in profound myelosuppression and should be avoided. Chronic immunosuppression increases the risk of serious infections; may require dosage reduction; response to vaccines may be diminished.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The development of secondary hemophagocytic lymphohistiocytosis (HLH), a rare and frequently fatal activation of macrophages which causes phagocytosis of all bone marrow blood cell lines, is increased (100-fold) in pediatric patients diagnosed with inflammatory bowel disease due to chronic inflammation; this risk is further increased with concomitant thiopurine (ie, azathioprine or mercaptopurine) therapy, Epstein-Barr virus or possibly other infections; if patient on thiopurine therapy presents with fever for at least 5 days, cervical lymphadenopathy and lymphopenia, discontinue immunosuppressive therapy and further diagnostic evaluation for HLH should be performed; delay in diagnosis has been associated with increased mortality (Biank, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe nausea, vomiting, diarrhea, rash, fever, malaise, myalgia, hypotension, and liver enzyme abnormalities may occur within the first several weeks of treatment and are generally reversible upon discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May decrease the metabolism of AzaTHIOprine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May increase the serum concentration of AzaTHIOprine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: AzaTHIOprine may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased. Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfamethoxazole: May enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): AzaTHIOprine may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): AzaTHIOprine may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1620142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Azathioprine was found to be teratogenic in animal studies; temporary depression in spermatogenesis and reduction in sperm viability and sperm count were also reported in mice. Azathioprine crosses the placenta in humans; congenital anomalies, immunosuppression, hematologic toxicities (lymphopenia, pancytopenia), and intrauterine growth retardation have been reported. There are no adequate and well-controlled studies in pregnant women. Azathioprine should not be used to treat rheumatoid arthritis during pregnancy. The potential benefit to the mother versus possible risk to the fetus should be considered when treating other disease states. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC  with differential and platelets (weekly during first month, twice monthly for months 2 and 3, then monthly; monitor more frequently with dosage modifications), total bilirubin, liver function tests, creatinine clearance, TPMT genotyping or phenotyping (consider TPMT testing in patients with abnormally low CBC unresponsive to dose reduction); monitor for symptoms of infection",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For  use as immunomodulatory therapy in inflammatory bowel disease, monitor CBC with differential weekly for 1 month, then biweekly for 1 month, followed by monitoring every 1-2 months throughout the course of therapy; monitor more frequently if symptomatic. LFTs should be assessed every 3 months. Monitor for signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antagonizes purine metabolism and may inhibit synthesis of DNA, RNA, and proteins; may also interfere with cellular metabolism and inhibit mitosis. Cytotoxicity of azathioprine is partially due to incorporation of 6-thioguanine nucleotides into DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, to 6-mercaptopurine, possibly by glutathione S-transferase (GST). Further metabolism of 6-mercaptopurine (in the liver and GI tract), via three major pathways: Hypoxanthine guanine phosphoribosyltransferase (to active metabolites: 6-thioguanine-nucleotides, or 6-TGNs), xanthine oxidase (to inactive metabolite: 6-thiouric acid), and thiopurine methyltransferase (TPMT) (to inactive metabolite: 6-methylmercaptopurine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-2 hours (including metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parent: 12 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-mercaptopurine: 0.7-3 hours; End-stage renal disease: Slightly prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (primarily as metabolites; small amount as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 45% removed during 8-hour session",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/31/28149?source=see_link\">",
"      see \"Azathioprine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May take in divided doses or with food if GI upset occurs. Susceptibility to infection may be increased. May cause nausea, vomiting, loss of appetite. Report abdominal pain and unresolved GI upset (eg, persistent vomiting or diarrhea); unusual fever or chills; bleeding or bruising; sore throat, unhealed sores, or signs of infection; yellowing of skin or eyes; signs of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss); or change in color of urine or stool. For rheumatoid arthritis, response may not occur for up to 3 months. For organ transplant, azathioprine will usually be prescribed with other antirejection medications. Avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F6855103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection, powder for reconstitution, as sodium: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F138200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 50 mg/mL oral suspension may be prepared with tablets. Crush one-hundred-twenty 50 mg tablets in a mortar and reduce to a fine powder. Add 40 mL of either cherry syrup (diluted 1:4 with Simple Syrup, USP); a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;, and mix to a uniform paste. Mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\", \"refrigerate\", and &ldquo;protect from light&rdquo;. Stable for 60 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(16):1944-9.",
"     <span class=\"pubmed-id\">",
"      8862208",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams A, MacDermott EJ, and Lehman TJ, \"Pharmacotherapy of Lupus Nephritis in Children: A Recommended Treatment Approach,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2006, 66(9):1191-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/16827597/pubmed\" id=\"16827597\" target=\"_blank\">",
"        16827597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians, 2007, p. 97, 177.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ashraf VV, Taly AB, Veerendrakumar M, et al, \"Myasthenia Gravis in Children: A Longitudinal Study,\"",
"      <i>",
"       Acta Neurol Scand",
"      </i>",
"      , 2006, 114(2):119-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/16867035/pubmed\" id=\"16867035\" target=\"_blank\">",
"        16867035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bertsias GK, Tektonidou M, Amoura Z, et al, \"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations for the Management of Adult and Paediatric Lupus Nephritis,\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2012, 71(11):1771-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/22851469/pubmed\" id=\"22851469\" target=\"_blank\">",
"        22851469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biank VF, Sheth MK, Talano J, et al, \"Association of Crohn's Disease, Thiopurines, and Primary Epstein-Barr Virus Infection With Hemophagocytic Lymphohistiocytosis,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2011, 159(5):808-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/21722918/pubmed\" id=\"21722918\" target=\"_blank\">",
"        21722918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boruchov DM, Gururangan S, Driscoll MC, et al, \"Multiagent Induction and Maintenance Therapy for Patients With Refractory Immune Thrombocytopenic Purpura (ITP),\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(10):3526-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/17698634/pubmed\" id=\"17698634\" target=\"_blank\">",
"        17698634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Della Corte C, Sartorelli MR, Sindoni CD, et al, \"Autoimmune Hepatitis in Children: An Overview of the Disease Focusing on Current Therapies,\"",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2012, 24(7):739-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/22495399/pubmed\" id=\"22495399\" target=\"_blank\">",
"        22495399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Denfield SW, \"Strategies to Prevent Cellular Rejection in Pediatric Heart Transplant Recipients,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2010, 12(6):391-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/21028918/pubmed\" id=\"21028918\" target=\"_blank\">",
"        21028918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ford KA, \"Paediatric Immunosuppression Following Solid Organ Transplantation,\"",
"      <i>",
"       Arch Dis Child Educ Pract",
"      </i>",
"      , 2006, 91:ep87-ep91.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuentes D, Torrente F, Keady S, et al, \"High-Dose Azathioprine in Children With Inflammatory Bowel Disease,\"",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2003, 17(7):913-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/12656694/pubmed\" id=\"12656694\" target=\"_blank\">",
"        12656694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goebel JC, Roesel M, Heinz C, et al, \"Azathioprine as a Treatment Option for Uveitis in Patients With Juvenile Idiopathic Arthritis,\"",
"      <i>",
"       Br J Ophthalmol",
"      </i>",
"      , 2011, 95(2):209-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/20584711/pubmed\" id=\"20584711\" target=\"_blank\">",
"        20584711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grossman AB, Noble AJ, Mamula P, et al, \"Increased Dosing Requirements for 6-Mercaptopurine and Azathioprine in Inflammatory Bowel Disease Patients Six Years and Younger,\"",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2008, 14(6):750-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/18266236/pubmed\" id=\"18266236\" target=\"_blank\">",
"        18266236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hashkes PJ and Laxer RM, \"Medical Treatment of Juvenile Idiopathic Arthritis,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2005, 294(13):1671-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/16204667/pubmed\" id=\"16204667\" target=\"_blank\">",
"        16204667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson CA and Porter WA, &ldquo;Compatibility of Azathioprine Sodium With Intravenous Fluids,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1981, 38(6):871-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/7246562/pubmed\" id=\"7246562\" target=\"_blank\">",
"        7246562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kemper AR, Coeytaux R, Sanders GD, et al, \"Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA),\" Agency for Healthcare Research and Quality, AHRQ Comparative Effectiveness Reviews, 2011.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/22091470/pubmed\" id=\"22091470\" target=\"_blank\">",
"        22091470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kvien TK, Hoyeraal HM, and Sandstad B, \"Azathioprine Versus Placebo in Patients With Juvenile Rheumatoid Arthritis: A Single Center Double Blind Comparative Study,\"",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1986, 13(1):118-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/3517321/pubmed\" id=\"3517321\" target=\"_blank\">",
"        3517321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leichter HE, Sheth KJ, Gerlach MJ, et al, &ldquo;Outcome of Renal Transplantation in Children Aged 1-5 and 6-18 Years,&rdquo;",
"      <i>",
"       Child Nephrol Urol",
"      </i>",
"      , 1992, 12(1):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/1606573/pubmed\" id=\"1606573\" target=\"_blank\">",
"        1606573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindner A, Schalke B, and Toyka KV, \"Outcome in Juvenile-Onset Myasthenia Gravis: A Retrospective Study With Long-Term Follow-Up of 79 Patients,\"",
"      <i>",
"       J Neurol",
"      </i>",
"      , 1997, 244(8):515-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/9309559/pubmed\" id=\"9309559\" target=\"_blank\">",
"        9309559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marks SD and Tullus K, \"Modern Therapeutic Strategies for Paediatric Systemic Lupus Erythematosus and Lupus Nephritis,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2010, 99(7):967-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/20222881/pubmed\" id=\"20222881\" target=\"_blank\">",
"        20222881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palace J, Newsom-Davis J, and Lecky B, \"A Randomized Double-Blind Trial of Prednisolone Alone or With Azathioprine in Myasthenia Gravis. Myasthenia Gravis Study Group,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1998, 50(6):1778-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/9633727/pubmed\" id=\"9633727\" target=\"_blank\">",
"        9633727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Punati J, Markowitz J, Lerer T, et al, \"Effect of Early Immunomodulator Use in Moderate to Severe Pediatric Crohn Disease,\"",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2008, 14(7):949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/18306311/pubmed\" id=\"18306311\" target=\"_blank\">",
"        18306311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riello L, Talbotec C, Garnier-Lenglin&eacute; H, et al, \"Tolerance and Efficacy of Azathioprine in Pediatric Crohn's Disease,\"",
"      <i>",
"       Inflamm Bowel Dis",
"      </i>",
"      , 2011, 17(10):2138-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/21910176/pubmed\" id=\"21910176\" target=\"_blank\">",
"        21910176",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandhu BK, Fell JME, Beattie RM, et al, \"Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom,\"",
"      <i>",
"       JPGN",
"      </i>",
"      , 2010, 50:S1-S13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sathasivam S, \"Steroids and Immunosuppressant Drugs in myasthenia Gravis,\"",
"      <i>",
"       Nat Clin Pract Neurol",
"      </i>",
"      , 2008, 4(6):317-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/18493241/pubmed\" id=\"18493241\" target=\"_blank\">",
"        18493241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vitfell-Pedersen J, Jorgensen MH, M&uuml;ller K, et al, \"Autoimmune Hepatitis in Children in Eastern Denmark,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2012, 55(4):376-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/10/2216/abstract-text/22644464/pubmed\" id=\"22644464\" target=\"_blank\">",
"        22644464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12923 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2216=[""].join("\n");
var outline_f2_10_2216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708623\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138216\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138217\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045373\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045366\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138195\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138180\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045376\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138269\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045369\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045375\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138271\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138268\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045380\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045365\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045364\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298801\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138189\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138191\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1620142\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045372\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045363\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045379\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045371\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855103\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138200\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12923\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12923|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=related_link\">",
"      Azathioprine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/31/28149?source=related_link\">",
"      Azathioprine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_10_2217="Capillary malformations (port wine stains): Clinical features, diagnosis, and associated syndromes";
var content_f2_10_2217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Capillary malformations (port wine stains): Clinical features, diagnosis, and associated syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2217/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2217/contributors\">",
"     Sheila Galbraith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2217/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2217/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2217/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/10/2217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31576694\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary malformations (port wine stains or nevus flammeus) are low-flow vascular malformations of dermal capillaries and postcapillary venules. They are present at birth as blanchable pink to red patches and may be located anywhere on the body, typically with a unilateral or segmental distribution that respects the midline. Capillary malformations do not regress, but grow in proportion to the child&rsquo;s growth and become thicker and darker in color during adulthood. Although capillary malformations are most often isolated skin anomalies, they may be associated with complex malformation syndromes. (See",
"    <a class=\"local\" href=\"#H3700607\">",
"     'Associated syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pathogenesis, clinical presentation, and associated syndromes of capillary malformations will be discussed here. Laser treatment of capillary malformations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H10061356#H10061356\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Port wine stains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1172065\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study and literature review, capillary malformations occurred in 0.1 to 2 percent of newborns without sex predilection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/1\">",
"     1",
"    </a>",
"    ]. They are generally sporadic, but familial cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962310\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and pathogenesis of capillary malformations are unknown. Several mechanisms may be involved in their development, including vascular ectasia, lack of neuronal control of blood flow, overexpression of vascular endothelial growth factor (VEGF) and VEGF receptor, and development of compensatory, collateral passageways for venous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inactivating mutations in the",
"    <em>",
"     RASA1",
"    </em>",
"    gene, which cause the autosomal dominant capillary malformation-arteriovenous malformation syndrome, may be involved in hereditary cases of capillary malformations without arteriovenous malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. The",
"    <em>",
"     RAS",
"    </em>",
"    gene family encodes membrane-associated proteins that are involved in the control of cell proliferation and differentiation and organization of endothelial cells into highly organized networks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435476\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of port wine stains reveals ectatic capillaries and postcapillary venules in the papillary and reticular dermis. The number of vessels is not increased and there is no endothelial proliferation. Later-stage lesions develop progressive fibrosis around the vessels and dilatation of the channels. Decreased nerve density has been demonstrated within affected areas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31576703\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89685844\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary malformations are present at birth as partially or completely blanchable pink to red patches, with unilateral or segmental distribution that respects the midline (",
"    <a class=\"graphic graphic_picture graphicRef59124 \" href=\"UTD.htm?18/32/18946\">",
"     picture 4B",
"    </a>",
"    ). Lesions are flat, painless, and the same temperature as surrounding skin.",
"   </p>",
"   <p>",
"    The face is a common location, but capillary malformations can occur anywhere on the body (",
"    <a class=\"graphic graphic_picture graphicRef54078 \" href=\"UTD.htm?33/24/34177\">",
"     picture 1",
"    </a>",
"    ). On the face, they tend to follow the distribution of the trigeminal nerve branches (segments V1 [ophthalmic], V2 [maxillary], and V3 [mandibular]) (",
"    <a class=\"graphic graphic_picture graphicRef73978 \" href=\"UTD.htm?0/45/722\">",
"     picture 4C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52850 \" href=\"UTD.htm?16/42/17065\">",
"     figure 1",
"    </a>",
"    ). Facial lesions may extend into the mucosal surfaces of the lips and gingivae.",
"   </p>",
"   <p>",
"    In most cases, capillary malformations are isolated cutaneous anomalies. However, they may be associated with other abnormalities (eg, glaucoma and occult spinal dysraphism) or be a component of complex malformation syndromes (eg, Sturge-Weber or Klippel Trenaunay syndrome). (See",
"    <a class=\"local\" href=\"#H830742\">",
"     'Associated abnormalities/complications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3700607\">",
"     'Associated syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802772\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary malformations do not regress over time, but grow proportionally with the child&rsquo;s growth. Untreated lesions may become thicker, darker in color (port wine), and nodular in adulthood (",
"    <a class=\"graphic graphic_picture graphicRef58831 \" href=\"UTD.htm?21/53/22367\">",
"     picture 2",
"    </a>",
"    ). In a series of 173 patients with capillary malformations with a median age of 29 years, thickening was observed in 11 percent of patients, nodularity in 24 percent, and both in 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830742\">",
"    <span class=\"h2\">",
"     Associated abnormalities/complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6789835\">",
"    <span class=\"h3\">",
"     Glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective study of 216 children with periocular capillary malformations, 18 percent had glaucoma at presentation or developed glaucoma during a median follow-up of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/12\">",
"     12",
"    </a>",
"    ]. Glaucoma was more common in patients with bilateral port wine stains or involvement of the upper and lower eyelids (distribution areas of V1 and V2 trigeminal branches). A higher prevalence of glaucoma of 40 to 60 percent has been reported in case series of patients with facial capillary malformations associated with Sturge-Weber syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Early-onset glaucoma occurs before age four and causes eye enlargement (buphthalmos), whereas late-onset glaucoma may be delayed until adolescence and is not associated with buphthalmos [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of glaucoma in infants and children\", section on 'Secondary glaucoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with facial capillary malformation and glaucoma, brain imaging studies are recommended to exclude leptomeningeal involvement and Sturge-Weber syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=see_link&amp;anchor=H15#H15\">",
"     \"Sturge-Weber syndrome\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801764\">",
"    <span class=\"h3\">",
"     Occult spinal dysraphism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between isolated capillary malformations located over the lumbar spine and spinal dysraphism is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. However, imaging studies to rule out occult spinal dysraphism are recommended when capillary malformations occur in conjunction with other cutaneous abnormalities (eg, hypertrichosis, dermal sinus or pit, lipomas, or deviated gluteal cleft) in the midline lumbosacral area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=see_link\">",
"     \"Pathogenesis and types of occult spinal dysraphism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6789856\">",
"    <span class=\"h3\">",
"     Soft tissue and bone overgrowth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone overgrowth are complications of capillary malformations patients. Maxillary bone and gingival hyperplasia, lip enlargement, and abnormal bite may occur with facial capillary malformations in the V2 distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/20\">",
"     20",
"    </a>",
"    ]. Overgrowth of digits or limbs also may occur with reticulated or extensive lesions localized to the limbs. [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/21\">",
"     21",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6789863\">",
"    <span class=\"h3\">",
"     Thickening and nodularity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In large case series, skin thickening or &ldquo;cobblestoning&rdquo; with nodular growths within the capillary malformation occurs in up to 65 percent of lesions, especially within those located on the face (",
"    <a class=\"graphic graphic_picture graphicRef58831 \" href=\"UTD.htm?21/53/22367\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/11,22,23\">",
"     11,22,23",
"    </a>",
"    ]. On histologic examination, most nodules are pyogenic granulomas (",
"    <a class=\"graphic graphic_picture graphicRef83687 \" href=\"UTD.htm?6/57/7060\">",
"     picture 3",
"    </a>",
"    ), arteriovenous malformations, or vascular ectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Easy bleeding within these lesions is common.",
"   </p>",
"   <p>",
"    Early treatment may prevent thickening and development of nodularity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H175203904#H175203904\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Lesion characteristics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686176\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686219\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of capillary malformations is in most cases clinical and based upon the appearance, time of onset, and temporal evolution of the skin lesion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In newborns and children, blanchable pink to red patches, often with unilateral distribution and midline demarcation (",
"      <a class=\"graphic graphic_picture graphicRef83601 graphicRef59124 graphicRef73978 \" href=\"UTD.htm?26/57/27545\">",
"       picture 4A-C",
"      </a>",
"      ); in adults, red to purple plaques with &ldquo;cobblestoning&rdquo; and nodular growths (",
"      <a class=\"graphic graphic_picture graphicRef58831 \" href=\"UTD.htm?21/53/22367\">",
"       picture 2",
"      </a>",
"      ). Soft-tissue and bone overgrowth may be noted in children and adults. (See",
"      <a class=\"local\" href=\"#H31576703\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence at birth without regression over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Growth in proportion to body growth; hyperplastic changes of the skin and underlying tissues over time in untreated lesions. (See",
"      <a class=\"local\" href=\"#H802772\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686226\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies (ultrasonography or magnetic resonance) are not routinely performed in children with capillary malformations. However, imaging studies may be necessary in the evaluation of associated syndromes including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance imaging (MRI) of the brain to exclude Sturge-Weber in children with facial capillary malformation involving more than one trigeminal segment (",
"      <a class=\"graphic graphic_figure graphicRef52850 \" href=\"UTD.htm?16/42/17065\">",
"       figure 1",
"      </a>",
"      ) or with neurologic symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=see_link&amp;anchor=H15#H15\">",
"       \"Sturge-Weber syndrome\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ultrasonography to identify venous varicosities in children with Klippel-Trenaunay syndrome or exclude an associated fast-flow arteriovenous malformation in children with symptomatic capillary malformations (warm to the touch or painful). (See",
"      <a class=\"local\" href=\"#H3700621\">",
"       'Klippel-Trenaunay syndrome'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3700628\">",
"       'Parkes-Weber syndrome'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3700656\">",
"       'Capillary malformation-arteriovenous malformation syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      MRI or computed tomography to exclude occult spinal dysraphism in children with midline lumbosacral capillary malformations associated with other cutaneous abnormalities (eg, hypertrichosis, dermal sinus or pit, lipomas, or deviated gluteal cleft). (See",
"      <a class=\"local\" href=\"#H801764\">",
"       'Occult spinal dysraphism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686233\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of capillary malformations includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nevus simplex",
"      </strong>",
"      &ndash; Nevus simplex, also called salmon patch or stork bite, is a common birthmark occurring in up to 80 percent of newborns [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/1\">",
"       1",
"      </a>",
"      ]. It is similar in appearance to capillary malformations but has more indistinct borders and is usually located in the midline. The most common locations are the glabella, upper eyelids, and nape of the neck (",
"      <a class=\"graphic graphic_picture graphicRef70234 \" href=\"UTD.htm?18/38/19040\">",
"       picture 5",
"      </a>",
"      ), but they can also be present in other locations including the forehead (",
"      <a class=\"graphic graphic_picture graphicRef83580 \" href=\"UTD.htm?33/5/33875\">",
"       picture 6",
"      </a>",
"      ), nose, upper and lower cutaneous lip, philtrum, scalp, and the upper, mid, and lower back [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/31\">",
"       31",
"      </a>",
"      ]. Unlike capillary malformations, these lesions (with the exception of those located on the nape of the neck) fade spontaneously over time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link&amp;anchor=H4#H4\">",
"       \"Vascular lesions in the newborn\", section on 'Nevus simplex (macular stain)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Infantile hemangioma",
"      </strong>",
"      &ndash; In about one-third of cases, infantile hemangioma is present at birth as a macular telangiectatic patch similar in appearance to a capillary malformation (",
"      <a class=\"graphic graphic_picture graphicRef65721 \" href=\"UTD.htm?19/60/20416\">",
"       picture 7",
"      </a>",
"      ). Hemangiomas with this presentation often have surrounding pallor representing vasoconstriction, which can help to differentiate them from capillary malformations early on. However, in contrast with capillary malformations, hemangiomas quickly begin to develop small vascular blebs and become raised. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"       \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Arteriovenous malformation",
"      </strong>",
"      &ndash; Arteriovenous malformations may present as macular vascular patches (",
"      <a class=\"graphic graphic_picture graphicRef83553 \" href=\"UTD.htm?35/11/36017\">",
"       picture 8C",
"      </a>",
"      ). However, they are often warm to the touch and a thrill may be felt on palpation. Over time, arteriovenous malformations become progressively raised and develop a deep component (",
"      <a class=\"graphic graphic_picture graphicRef83576 graphicRef83577 \" href=\"UTD.htm?31/0/31750\">",
"       picture 8A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Linear scleroderma",
"      </strong>",
"      &ndash; Linear scleroderma (morphea) of the face, particularly the &ldquo;en coup de sabre&rdquo; form, may rarely present at birth as an erythematous patch and mimic a capillary malformation (",
"      <a class=\"graphic graphic_picture graphicRef83578 \" href=\"UTD.htm?22/0/22532\">",
"       picture 9A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. Over time, these lesions develop induration and atrophy typical of scleroderma (",
"      <a class=\"graphic graphic_picture graphicRef83579 \" href=\"UTD.htm?10/61/11221\">",
"       picture 9B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=see_link\">",
"       \"Localized scleroderma in childhood\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686922\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates presenting with a capillary malformation involving the upper and lower eyelids and the frontotemporal region (V1 and V2 segments) should be referred for ophthalmologic examination to rule out glaucoma. (See",
"    <a class=\"local\" href=\"#H6789835\">",
"     'Glaucoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children with a facial capillary malformation and neurologic symptoms, particularly seizures, should be referred for neurologic examination and neuroimaging studies to exclude Sturge-Weber syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=see_link&amp;anchor=H15#H15\">",
"     \"Sturge-Weber syndrome\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686929\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary malformations may be disfiguring and a source of significant psychological stress for patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/34\">",
"     34",
"    </a>",
"    ]. The goals of treatment are cosmetic improvement (reduction of skin redness) and prevention of complications (eg, thickening, nodularity, or bleeding) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/35-38\">",
"     35-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulsed dye laser (PDL) therapy is considered the standard of care for the treatment of capillary malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/39\">",
"     39",
"    </a>",
"    ]. It is based on the concept of selective photothermolysis with oxyhemoglobin as the target [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/40\">",
"     40",
"    </a>",
"    ]. PDL treatment irreversibly damages the capillary vessel wall with minimal damage to the overlying epidermis, which leads to lightening of the port wine stain without scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PDL therapy for capillary malformations is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H10061356#H10061356\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Port wine stains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700607\">",
"    <span class=\"h1\">",
"     ASSOCIATED SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700614\">",
"    <span class=\"h2\">",
"     Sturge-Weber syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sturge-Weber syndrome (SWS) is a rare congenital disorder characterized by the classic triad of facial port wine stain, leptomeningeal angiomatosis, and ocular involvement. The capillary malformation associated with SWS usually occurs in the distribution area of the ophthalmic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maxillary branch (segments",
"    <span class=\"nowrap\">",
"     V1/V2)",
"    </span>",
"    of the trigeminal nerve (",
"    <a class=\"graphic graphic_figure graphicRef52850 \" href=\"UTD.htm?16/42/17065\">",
"     figure 1",
"    </a>",
"    ), involves both the upper and lower eyelids, and is often bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of Sturge-Weber syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=see_link\">",
"     \"Sturge-Weber syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700621\">",
"    <span class=\"h2\">",
"     Klippel-Trenaunay syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary malformations, venous and lymphatic malformations, and soft tissue and bone hypertrophy involving a limb are prominent features of Klippel-Trenaunay syndrome (KTS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/43\">",
"     43",
"    </a>",
"    ]. The lower limbs, sometimes with extension to the trunk, are more frequently involved than the upper limbs.",
"   </p>",
"   <p>",
"    The capillary malformations are present at birth as extensive, geographic patches located on an extremity. Limb hypertrophy, resulting from soft tissue and bone overgrowth and underlying lymphatic abnormalities, may be apparent at birth or may develop later and progress until the end of puberty.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging and magnetic resonance venography can be helpful in evaluating the extent of",
"    <span class=\"nowrap\">",
"     venous/lymphatic",
"    </span>",
"    malformation and soft tissue and bone hypertrophy.",
"   </p>",
"   <p>",
"    Complications of KTS include deep vein thrombosis, pulmonary embolism, gastrointestinal bleeding, and vascular (usually lymphatic) blebs within the capillary malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700628\">",
"    <span class=\"h2\">",
"     Parkes-Weber syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkes-Weber syndrome is characterized by a large capillary malformation on an extremity, soft tissue and bone hypertrophy of the affected limb, and multiple, microscopic, fast-flow arteriovenous shunts. The capillary malformation of Parkes-Weber syndrome is indistinguishable from the port wine stain seen in KTS. Ultrasonography, MRI, and magnetic resonance arteriography are helpful in differentiating Parkes-Weber syndrome from KTS.",
"   </p>",
"   <p>",
"    Patients with Parkes-Weber syndrome have progressive overgrowth of the affected limb and complications related to the arteriovenous shunts, including ulcerations and high-output cardiac failure, especially in the neonatal period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700635\">",
"    <span class=\"h2\">",
"     Servelle-Martorell syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Servelle-Martorell syndrome is a rare congenital angiodysplastic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/45\">",
"     45",
"    </a>",
"    ]. It manifests with capillary malformations and varicosities similar to KTS, but is associated with progressive limb hypotrophy rather than overgrowth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700642\">",
"    <span class=\"h2\">",
"     Proteus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteus syndrome is an extremely rare disorder characterized by asymmetric and disproportionate overgrowth of body parts (",
"    <a class=\"graphic graphic_picture graphicRef83559 \" href=\"UTD.htm?10/56/11139\">",
"     picture 10",
"    </a>",
"    ). Mosaicism for a somatic activating mutation in the",
"    <em>",
"     AKT1",
"    </em>",
"    oncogene is thought to be the cause of Proteus syndrome.",
"   </p>",
"   <p>",
"    Cutaneous findings are present in about 40 percent of neonates and include capillary, lymphatic, or venous malformations, epidermal nevi, connective tissue nevi, lipomas, and caf&eacute; au lait macules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/46\">",
"     46",
"    </a>",
"    ]. The vascular malformations are usually extensive, covering a large portion of the body, and may be associated with visceral vascular malformations. Overgrowth is evident at birth in about 20 percent of cases and is asymmetric, disproportionate, and progressive. It may involve many tissues including bone, cartilage, muscle, and connective tissue.",
"   </p>",
"   <p>",
"    The diagnosis and management of Proteus syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462460056#H462460056\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Proteus and Proteus-like syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700649\">",
"    <span class=\"h2\">",
"     Bannayan-Riley-Ruvalcaba syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bannayan-Riley-Ruvalcaba syndrome is an autosomal dominant disorder caused by mutations in the tumor suppressor gene",
"    <em>",
"     PTEN",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/47\">",
"     47",
"    </a>",
"    ]. Cutaneous features include capillary, venous, and lymphatic malformations as well as lipomas and pigmented macules on the genitalia. Associated findings include macrocephaly, pseudopapilledema, mental retardation, and juvenile intestinal polyposis.",
"   </p>",
"   <p>",
"    Bannayan-Riley-Ruvalcaba syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462460023#H462460023\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Bannayan-Riley-Ruvalcaba syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700656\">",
"    <span class=\"h2\">",
"     Capillary malformation-arteriovenous malformation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant disorder caused by mutations in the",
"    <em>",
"     RASA1",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <em>",
"     RASA1",
"    </em>",
"    encodes the protein involved in the control of cell proliferation and differentiation and organization of endothelial cells into highly organized networks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CM-AVM syndrome is characterized by atypical cutaneous capillary malformations in conjunction with an AVM. The AVM can be localized or diffuse and can be located in the soft tissues, muscles, bones, brain, or spine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The capillary malformations are usually multiple, round to oval, pink-red or tan patches of 1 to 2 cm in size scattered randomly on the body. New lesions may continue to appear throughout childhood. A high flow murmur can usually be detected over the lesions with a hand-held Doppler device [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler ultrasonography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI and magnetic resonance arteriography of clinically involved areas and brain are needed to evaluate the extension of AVM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700663\">",
"    <span class=\"h2\">",
"     Macrocephaly-capillary malformation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrocephaly-capillary malformation (M-CM) syndrome (previously named macrocephaly-cutis marmorata telangiectatica congenita) is a genetic syndrome of unknown etiology characterized by an enlarged head circumference and patchy, reticular capillary malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is based upon the presence of two major clinical criteria and at least two minor criteria.",
"   </p>",
"   <p>",
"    Major criteria are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Macrocephaly",
"     </li>",
"     <li>",
"      Capillary malformation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minor criteria are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymmetry or overgrowth",
"     </li>",
"     <li>",
"      Developmental delay",
"     </li>",
"     <li>",
"      Hypotonia",
"     </li>",
"     <li>",
"      Syndactyly or polydactyly",
"     </li>",
"     <li>",
"      Frontal bossing",
"     </li>",
"     <li>",
"      Hydrocephalus",
"     </li>",
"     <li>",
"      Connective tissue abnormalities such as joint hypermobility or hyperelastic skin",
"     </li>",
"     <li>",
"      Midline facial nevus simplex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The capillary malformations are usually reticulated and widespread on the trunk and extremities. Cardiac abnormalities including aortic coarctation have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Neuroimaging findings include white matter abnormalities, ventriculomegaly, cerebral asymmetry, cortical dysplasia, polymicrogyria-like changes, and cerebellar tonsil herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700670\">",
"    <span class=\"h2\">",
"     Beckwith-Wiedemann syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beckwith-Wiedemann syndrome is a congenital overgrowth syndrome with major features including anterior abdominal wall defects, macroglossia, gigantism, and a propensity to develop specific tumors (hepatoblastoma, Wilms tumour, neuroblastoma, and rhabdomyosarcoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Infants have centrofacial capillary malformations similar to nevus simplex in the majority of cases. Vascular lesions may extend to the upper eyelids, upper lip, and nose. Characteristic-associated findings are an anterior ear lobe crease and posterior helical ear pits.",
"   </p>",
"   <p>",
"    Beckwith-Wiedemann syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3700677\">",
"    <span class=\"h2\">",
"     Phakomatosis pigmentovascularis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phakomatosis pigmentovascularis is a syndrome characterized by the association of a widespread capillary malformation with pigmented lesions including dermal melanocytosis, nevus spilus, mosaic hyperpigmentation, and epidermal nevus. Nevus anemicus and caf&eacute; au lait spots can be associated findings. Extracutaneous findings include visceral, muscular, neurologic, or ocular abnormalities.",
"   </p>",
"   <p>",
"    Five types of phakomatosis pigmentovascularis have been identified based upon the type of pigmented lesion associated with the capillary malformation; for each type, subtype &ldquo;a&rdquo; denotes absence and subtype &ldquo;b&rdquo; presence of extracutaneous findings (",
"    <a class=\"graphic graphic_table graphicRef83711 \" href=\"UTD.htm?8/46/8939\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2217/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14531711\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Capillary malformations (port wine stains or nevus flammeus) are low-flow vascular malformations of dermal capillaries and postcapillary venules. (See",
"      <a class=\"local\" href=\"#H31576694\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Characteristic clinical features include blanchable pink to red patches located anywhere on the body (",
"      <a class=\"graphic graphic_picture graphicRef54078 \" href=\"UTD.htm?33/24/34177\">",
"       picture 1",
"      </a>",
"      ), typically with a unilateral or segmental distribution that respects the midline (",
"      <a class=\"graphic graphic_picture graphicRef83601 graphicRef59124 graphicRef73978 \" href=\"UTD.htm?26/57/27545\">",
"       picture 4A-C",
"      </a>",
"      ). On the face, capillary malformations tend to follow the distribution of the trigeminal nerve branches (",
"      <a class=\"graphic graphic_picture graphicRef73978 \" href=\"UTD.htm?0/45/722\">",
"       picture 4C",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef52850 \" href=\"UTD.htm?16/42/17065\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H89685844\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lesions do not regress and, if left untreated, may become thicker, darker in color (port wine), and nodular in adulthood (",
"      <a class=\"graphic graphic_picture graphicRef58831 \" href=\"UTD.htm?21/53/22367\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H802772\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of capillary malformations can be made with a history and examination in patients with characteristic clinical features (",
"      <a class=\"graphic graphic_picture graphicRef83601 graphicRef59124 graphicRef73978 \" href=\"UTD.htm?26/57/27545\">",
"       picture 4A-C",
"      </a>",
"      ). Imaging studies (ultrasonography or magnetic resonance) may be necessary in the evaluation of associated syndromes or abnormalities. (See",
"      <a class=\"local\" href=\"#H89686176\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of capillary malformations includes nevus simplex (salmon patch or stork bite) (",
"      <a class=\"graphic graphic_picture graphicRef83580 \" href=\"UTD.htm?33/5/33875\">",
"       picture 6",
"      </a>",
"      ), infantile hemangioma (",
"      <a class=\"graphic graphic_picture graphicRef65721 \" href=\"UTD.htm?19/60/20416\">",
"       picture 7",
"      </a>",
"      ), arteriovenous malformation (",
"      <a class=\"graphic graphic_picture graphicRef83553 graphicRef83576 graphicRef83577 \" href=\"UTD.htm?12/42/12969\">",
"       picture 8A-C",
"      </a>",
"      ), and linear scleroderma (",
"      <a class=\"graphic graphic_picture graphicRef83578 graphicRef83579 \" href=\"UTD.htm?19/20/19785\">",
"       picture 9A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pulsed dye laser (PDL) therapy is considered the standard of care for the treatment of capillary malformations. PDL therapy for capillary malformations is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H10061356#H10061356\">",
"       \"Laser and light therapy for cutaneous vascular lesions\", section on 'Port wine stains'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In most cases, capillary malformations are isolated cutaneous anomalies. However, they may be associated with other abnormalities (eg, glaucoma and occult spinal dysraphism) or be a component of complex malformation syndromes (eg, Sturge-Weber or Klippel Trenaunay syndrome). (See",
"      <a class=\"local\" href=\"#H830742\">",
"       'Associated abnormalities/complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3700607\">",
"       'Associated syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/1\">",
"      Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr 2012; 161:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/2\">",
"      Hershkovitz D, Bercovich D, Sprecher E, Lapidot M. RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations. Br J Dermatol 2008; 158:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/3\">",
"      Eerola I, Boon LM, Watanabe S, et al. Locus for susceptibility for familial capillary malformation ('port-wine stain') maps to 5q. Eur J Hum Genet 2002; 10:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/4\">",
"      Breugem CC, Alders M, Salieb-Beugelaar GB, et al. A locus for hereditary capillary malformations mapped on chromosome 5q. Hum Genet 2002; 110:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/5\">",
"      Smoller BR, Rosen S. Port-wine stains. A disease of altered neural modulation of blood vessels? Arch Dermatol 1986; 122:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/6\">",
"      Vural E, Ramakrishnan J, Cetin N, et al. The expression of vascular endothelial growth factor and its receptors in port-wine stains. Otolaryngol Head Neck Surg 2008; 139:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/7\">",
"      Parsa CF. Sturge-weber syndrome: a unified pathophysiologic mechanism. Curr Treat Options Neurol 2008; 10:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/8\">",
"      Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003; 73:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/9\">",
"      Henkemeyer M, Rossi DJ, Holmyard DP, et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 1995; 377:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/10\">",
"      Chang CJ, Yu JS, Nelson JS. Confocal microscopy study of neurovascular distribution in facial port wine stains (capillary malformation). J Formos Med Assoc 2008; 107:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/11\">",
"      Klapman MH, Yao JF. Thickening and nodules in port-wine stains. J Am Acad Dermatol 2001; 44:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/12\">",
"      Khaier A, Nischal KK, Espinosa M, Manoj B. Periocular port wine stain: the great ormond street hospital experience. Ophthalmology 2011; 118:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/13\">",
"      Sharan S, Swamy B, Taranath DA, et al. Port-wine vascular malformations and glaucoma risk in Sturge-Weber syndrome. J AAPOS 2009; 13:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/14\">",
"      Hennedige AA, Quaba AA, Al-Nakib K. Sturge-Weber syndrome and dermatomal facial port-wine stains: incidence, association with glaucoma, and pulsed tunable dye laser treatment effectiveness. Plast Reconstr Surg 2008; 121:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/15\">",
"      Ch'ng S, Tan ST. Facial port-wine stains - clinical stratification and risks of neuro-ocular involvement. J Plast Reconstr Aesthet Surg 2008; 61:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/16\">",
"      Guggisberg D, Hadj-Rabia S, Viney C, et al. Skin markers of occult spinal dysraphism in children: a review of 54 cases. Arch Dermatol 2004; 140:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/17\">",
"      Ben-Amitai D, Davidson S, Schwartz M, et al. Sacral nevus flammeus simplex: the role of imaging. Pediatr Dermatol 2000; 17:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/18\">",
"      Metzker A, Shamir R. Butterfly-shaped mark: a variant form of nevus flammeus simplex. Pediatrics 1990; 85:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/19\">",
"      Patrizi A, Neri I, Orlandi C, Marini R. Sacral medial telangiectatic vascular nevus: a study of 43 children. Dermatology 1996; 192:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/20\">",
"      Dowling MB, Zhao Y, Darrow DH. Orodental manifestations of facial port-wine stains. J Am Acad Dermatol 2012; 67:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/21\">",
"      Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part I. J Am Acad Dermatol 2007; 56:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/22\">",
"      Mills CM, Lanigan SW, Hughes J, Anstey AV. Demographic study of port wine stain patients attending a laser clinic: family history, prevalence of naevus anaemicus and results of prior treatment. Clin Exp Dermatol 1997; 22:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/23\">",
"      Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991; 17:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/24\">",
"      Kim TH, Choi EH, Ahn SK, Lee SH. Vascular tumors arising in port-wine stains: two cases of pyogenic granuloma and a case of acquired tufted angioma. J Dermatol 1999; 26:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/25\">",
"      Swerlick RA, Cooper PH. Pyogenic granuloma (lobular capillary hemangioma) within port-wine stains. J Am Acad Dermatol 1983; 8:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/26\">",
"      Liu S, Yang C, Xu S, et al. Pyogenic granuloma arising as a complication of 595 nm tunable pulsed dye laser treatment of port-wine stains: report of four cases. Dermatol Surg 2010; 36:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/27\">",
"      Chen D, Hu XJ, Lin XX, et al. Nodules arising within port-wine stains: a clinicopathologic study of 31 cases. Am J Dermatopathol 2011; 33:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/28\">",
"      Alessi E, Bertani E, Sala F. Acquired tufted angioma. Am J Dermatopathol 1986; 8:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/29\">",
"      Piram M, Lorette G, Sirinelli D, et al. Sturge-Weber syndrome in patients with facial port-wine stain. Pediatr Dermatol 2012; 29:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/30\">",
"      Mazereeuw-Hautier J, Syed S, Harper JI. Bilateral facial capillary malformation associated with eye and brain abnormalities. Arch Dermatol 2006; 142:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/31\">",
"      Juern AM, Glick ZR, Drolet BA, Frieden IJ. Nevus simplex: a reconsideration of nomenclature, sites of involvement, and disease associations. J Am Acad Dermatol 2010; 63:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/32\">",
"      Nijhawan RI, Bard S, Blyumin M, et al. Early localized morphea mimicking an acquired port-wine stain. J Am Acad Dermatol 2011; 64:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/33\">",
"      Zulian F, Vallongo C, de Oliveira SK, et al. Congenital localized scleroderma. J Pediatr 2006; 149:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/34\">",
"      Lanigan SW, Cotterill JA. Psychological disabilities amongst patients with port wine stains. Br J Dermatol 1989; 121:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/35\">",
"      McClean K, Hanke CW. The medical necessity for treatment of port-wine stains. Dermatol Surg 1997; 23:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/36\">",
"      Wagner KD, Wagner RF Jr. The necessity for treatment of childhood port-wine stains. Cutis 1990; 45:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/37\">",
"      Strauss RP, Resnick SD. Pulsed dye laser therapy for port-wine stains in children: psychosocial and ethical issues. J Pediatr 1993; 122:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/38\">",
"      Hansen K, Kreiter CD, Rosenbaum M, et al. Long-term psychological impact and perceived efficacy of pulsed-dye laser therapy for patients with port-wine stains. Dermatol Surg 2003; 29:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/39\">",
"      Faurschou A, Olesen AB, Leonardi-Bee J, Haedersdal M. Lasers or light sources for treating port-wine stains. Cochrane Database Syst Rev 2011; :CD007152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/40\">",
"      Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/41\">",
"      Jasim ZF, Handley JM. Treatment of pulsed dye laser-resistant port wine stain birthmarks. J Am Acad Dermatol 2007; 57:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/42\">",
"      Tallman B, Tan OT, Morelli JG, et al. Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications. Pediatrics 1991; 87:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/43\">",
"      Jacob AG, Driscoll DJ, Shaughnessy WJ, et al. Klippel-Tr&eacute;naunay syndrome: spectrum and management. Mayo Clin Proc 1998; 73:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/44\">",
"      Huiras EE, Barnes CJ, Eichenfield LF, et al. Pulmonary thromboembolism associated with Klippel-Trenaunay syndrome. Pediatrics 2005; 116:e596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/45\">",
"      Marsden N, Shokrollahi K, Maw K, et al. Congenital vascular malformation associated with multiple cranial, vertebral and upper limb skeletal abnormalities. Ann R Coll Surg Engl 2010; 92:W18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/46\">",
"      Turner JT, Cohen MM Jr, Biesecker LG. Reassessment of the Proteus syndrome literature: application of diagnostic criteria to published cases. Am J Med Genet A 2004; 130A:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/47\">",
"      Marsh DJ, Dahia PL, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/48\">",
"      Thiex R, Mulliken JB, Revencu N, et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. AJNR Am J Neuroradiol 2010; 31:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/49\">",
"      Revencu N, Boon LM, Mulliken JB, et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 2008; 29:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/50\">",
"      Wright DR, Frieden IJ, Orlow SJ, et al. The misnomer \"macrocephaly-cutis marmorata telangiectatica congenita syndrome\": report of 12 new cases and support for revising the name to macrocephaly-capillary malformations. Arch Dermatol 2009; 145:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/51\">",
"      Mart&iacute;nez-Glez V, Romanelli V, Mori MA, et al. Macrocephaly-capillary malformation: Analysis of 13 patients and review of the diagnostic criteria. Am J Med Genet A 2010; 152A:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/52\">",
"      Toriello HV, Mulliken JB. Accurately renaming macrocephaly-cutis marmorata telangiectatica congenita (M-CMTC) as macrocephaly-capillary malformation (M-CM). Am J Med Genet A 2007; 143A:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/53\">",
"      Lapunzina P, Gair&iacute; A, Delicado A, et al. Macrocephaly-cutis marmorata telangiectatica congenita: report of six new patients and a review. Am J Med Genet A 2004; 130A:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/54\">",
"      Gonzalez ME, Burk CJ, Barbouth DS, Connelly EA. Macrocephaly-capillary malformation: a report of three cases and review of the literature. Pediatr Dermatol 2009; 26:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/55\">",
"      Conway RL, Pressman BD, Dobyns WB, et al. Neuroimaging findings in macrocephaly-capillary malformation: a longitudinal study of 17 patients. Am J Med Genet A 2007; 143A:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/56\">",
"      Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. Eur J Hum Genet 2010; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/57\">",
"      DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998; 132:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/58\">",
"      Fern&aacute;ndez-Guarino M, Boixeda P, de Las Heras E, et al. Phakomatosis pigmentovascularis: Clinical findings in 15 patients and review of the literature. J Am Acad Dermatol 2008; 58:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/59\">",
"      Torrelo A, Zambrano A, Happle R. Large aberrant Mongolian spots coexisting with cutis marmorata telangiectatica congenita (phacomatosis pigmentovascularis type V or phacomatosis cesiomarmorata). J Eur Acad Dermatol Venereol 2006; 20:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2217/abstract/60\">",
"      Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol 2005; 141:385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13726 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2217=[""].join("\n");
var outline_f2_10_2217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14531711\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31576694\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1172065\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H962310\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H435476\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31576703\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89685844\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802772\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H830742\">",
"      Associated abnormalities/complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6789835\">",
"      - Glaucoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H801764\">",
"      - Occult spinal dysraphism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6789856\">",
"      - Soft tissue and bone overgrowth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6789863\">",
"      - Thickening and nodularity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89686176\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89686219\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89686226\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89686233\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89686922\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89686929\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3700607\">",
"      ASSOCIATED SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700614\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700621\">",
"      Klippel-Trenaunay syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700628\">",
"      Parkes-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700635\">",
"      Servelle-Martorell syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700642\">",
"      Proteus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700649\">",
"      Bannayan-Riley-Ruvalcaba syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700656\">",
"      Capillary malformation-arteriovenous malformation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700663\">",
"      Macrocephaly-capillary malformation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700670\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3700677\">",
"      Phakomatosis pigmentovascularis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14531711\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13726|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/42/17065\" title=\"figure 1\">",
"      Anatomic distributions of the trigeminal nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13726|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/24/34177\" title=\"picture 1\">",
"      Port wine stain - leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/53/22367\" title=\"picture 2\">",
"      Adult with SWS and port wine stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/57/7060\" title=\"picture 3\">",
"      Port wine stain pyogenic granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/0/20481\" title=\"picture 4A\">",
"      Port wine stain midline demarcation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/32/18946\" title=\"picture 4B\">",
"      Port wine stain - V2 infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/45/722\" title=\"picture 4C\">",
"      Port wine stain - V2 child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/38/19040\" title=\"picture 5\">",
"      Salmon patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/5/33875\" title=\"picture 6\">",
"      Nevus simplex (salmon patch) forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/60/20416\" title=\"picture 7\">",
"      Infantile hemangioma - arrested growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/4/16448\" title=\"picture 8A\">",
"      Arteriovenous malformation gluteus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/0/23554\" title=\"picture 8B\">",
"      Arteriovenous malformation hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/11/36017\" title=\"picture 8C\">",
"      Cutaneous arteriovenous malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/0/22532\" title=\"picture 9A\">",
"      Linear scleroderma face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/61/11221\" title=\"picture 9B\">",
"      Linear scleroderma face 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/56/11139\" title=\"picture 10\">",
"      Proteus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13726|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/46/8939\" title=\"table 1\">",
"      Phakomatosis pigmentovascularis classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=related_link\">",
"      Pathogenesis and types of occult spinal dysraphism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4727?source=related_link\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_10_2218="Management of patients with a colostomy or ileostomy";
var content_f2_10_2218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of patients with a colostomy or ileostomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2218/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2218/contributors\">",
"     Dorothy B Doughty, MN, RN, CWOCN, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2218/contributors\">",
"     Ron G Landmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2218/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/10/2218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/10/2218/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/10/2218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal diversions may be required on either a temporary or permanent basis for the management of a variety of pathologic conditions, including congenital anomalies, obstructive or inflammatory disorders, traumatic disruption of the intestinal tract, or gastrointestinal malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/1\">",
"     1",
"    </a>",
"    ]. The number of permanent diversions is decreasing because of medical and surgical advances.",
"   </p>",
"   <p>",
"    Fecal diversions are commonly classified according to the segment of the bowel utilized (eg, sigmoid, colon, ileum)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical construction (eg, loop, end); both anatomic location and construction have an impact on management. Location of the ostomy (eg, whether it is proximal or distal to the ileocecal valve or proximal to the anus) tremendously impacts the type and volume of output (effluent). Ileostomies, cecostomies, and ascending colostomies typically produce &gt;500 mL per day of output containing digestive enzymes, while",
"    <span class=\"nowrap\">",
"     descending/sigmoid",
"    </span>",
"    colostomies produce stool that is formed and does not contain digestive enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Loop stomas are larger and somewhat more difficult to manage than end stomas. Any diversion involving retention of the distal bowel is normally accompanied by intermittent mucoid discharge from the anus.",
"   </p>",
"   <p>",
"    The surgical principles of construction of an ostomy and the management of parastomal hernia complications are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link\">",
"     \"Surgical principles of ostomy construction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"     \"Parastomal hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COLOSTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A colostomy is performed when it is necessary to bypass or remove the distal colon, rectum, or anus, and it is either inadvisable or not feasible to maintain integrity of the bowel. If the distal rectum and anorectal sphincter mechanism are removed, the colostomy is permanent; if the sphincter mechanism is retained, there is the potential for restoration of continuity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Temporary colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A temporary colostomy can be performed on an emergency basis to decompress an obstructed or perforated distal colon. A temporary \"diverting\" colostomy can also be performed electively to permit healing of a fistulous tract or acute inflammatory process distal to the colostomy. In addition, a diverting colostomy is sometimes created for protection of a distal anastomosis when delayed healing is anticipated (such as an anastomosis involving irradiated tissue); however, the procedure now favored for protection of a distal anastomosis is a diverting ileostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Decompressing colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obstructing lesions of the colon may require emergency decompression to prevent perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/7\">",
"     7",
"    </a>",
"    ]. Decompressing colostomies are constructed by bringing the loop of bowel to the abdominal surface and creating an opening into the anterior bowel wall; this provides a mechanism for evacuating fecal contents and also permits access to the obstructed bowel for bowel prep",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colonoscopy prior to a subsequent definitive surgical procedure. Decompressing colostomies also permit venting of air and liquid between the stoma and the obstruction. The decompressing colostomy also permits the dilated proximal bowel to regain normal caliber, which facilitates subsequent anastomosis. These stomas are generally performed in situations where there is maintenance of a competent ileocecal valve.",
"   </p>",
"   <p>",
"    The most commonly performed decompressing colostomies are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The transverse loop colostomy &ndash; the entire loop of bowel is brought out through the abdominal wall and sutured to the dermis or stabilized with a rod or bridge until the bowel granulates to the abdominal wall.",
"     </li>",
"     <li>",
"      Cecostomy &ndash; the anterior wall of the cecum is opened and sutured to an opening in the abdominal wall.",
"     </li>",
"     <li>",
"      The loop sigmoid colostomy &ndash; similar to the loop transverse colostomy and useful for patients with a redundant sigmoid colon and an obstructive rectal or anal cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these procedures are usually temporary. The major advantages of the decompressing colostomy include the ability to provide fecal diversion without transecting the bowel and risking major contamination of the abdominal cavity, and the ability to provide definitive management of the underlying disease process on an elective basis following a thorough work-up and a bowel prep if indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages of a decompressive colostomy include the requirement for additional surgery, and, for some patients, problems related to self-care and maintenance of a secure pouching system. Transverse loop colostomies are typically large stomas in the upper quadrants that are difficult to conceal, and cecostomies are typically skin-level stomas located adjacent to the groin crease, which compromises pouch adherence. There is also an increased rate of prolapse noted with transverse loop colostomies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diverting colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A colostomy can also be performed to divert the fecal stream proximal to a fistulous tract, an area of inflammation, or a distal anastomosis. In these settings, fecal diversion promotes healing of the involved site or quiescence of the disease process. Until recently, diverting colostomy has been the standard of care in cases involving acute intraabdominal sepsis following perforation or traumatic disruption of the bowel because primary anastomosis was thought to be unsafe. However, other studies consistently reveal lower morbidity and mortality rates when such patients are managed with primary anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/7,9-13\">",
"     7,9-13",
"    </a>",
"    ]. As a result, the role of diversion is being reevaluated. In addition, loop ileostomy has been shown to be a safer diversion with lower morbidity rates in situations where diversion is required, so the diverting colostomy is being used less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/5,14-17\">",
"     5,14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several approaches to construction of a temporary diverting colostomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A loop colostomy is created by bringing a loop of colon up to the abdominal wall. The ostomy is created with an afferent or proximal end that allows fecal diversion and a distal end that allows venting of the distal efferent",
"      <span class=\"nowrap\">",
"       limb/length",
"      </span>",
"      of bowel.",
"     </li>",
"     <li>",
"      A divided loop colostomy is created by exteriorizing a loop of colon, dividing the colon with a linear stapler, reducing the distal end into the subcutaneous space, removing the proximal staple line and suturing it to the dermis.",
"     </li>",
"     <li>",
"      A double barrel stoma is created by bringing both ends of the transected bowel to the abdominal wall as stomas (eg, a proximal functional colostomy and a distal mucous fistula).",
"     </li>",
"     <li>",
"      A Hartmann&rsquo;s procedure includes bringing the proximal end of the transected bowel to the abdominal wall as an end colostomy, and the distal end is oversewn and left in the abdominal cavity as a defunctional stump. The distal end may also be secured in place in the subcutaneous tissue as a mucous fistula, but not matured out to the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are advantages and disadvantages to each approach. All types of decompressing colostomies provide effective diversion and support healing of the distal bowel. The Hartmann&rsquo;s procedure is performed when there is a high likelihood of breakdown of the defunctionalized stump and consequent sepsis such as for cases of toxic colitis. All types of diverting ostomies can be performed laparoscopically or through an open approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Closure of a temporary colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, takedown of a temporary colostomy is delayed for weeks to months to assure complete resolution of the underlying condition and to permit softening of the adhesions. However, closure of the colostomy may be performed within three to six weeks if studies indicate that the need for diversion no longer exists (eg, if the distal anastomosis is well healed). Closure of the colostomy can be done laparoscopically or by an open procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Permanent colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent colostomy is most commonly performed for cancer involving the distal rectum or anus. Fortunately, it is now recognized that a 1 cm negative distal margin of resection is almost always sufficient to provide clear margins, which has reduced the number of patients with rectal cancer requiring a permanent colostomy. Endoanal stapling devices have also contributed to the reduction in permanent colostomies since they permit the surgeon to perform low stapled anastomoses in settings where hand-sewn anastomoses are not possible.",
"   </p>",
"   <p>",
"    Some studies have suggested that very low-lying rectal cancers can be safely removed with an intersphincteric resection (eg, partial resection of the internal anal sphincter), with minimal increase in morbidity and no significant increase in locoregional recurrence, so long as the resection extends to 1 cm below the tumor margin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Continence and stool frequency in these patients may be improved with construction of a coloanal reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/4,21,22\">",
"     4,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ILEOSTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ileostomy is performed when it is necessary to remove or bypass the entire colon and rectum, or to protect a distal colorectal, coloanal, or ileoanal anastomosis (",
"    <a class=\"graphic graphic_picture graphicRef70992 \" href=\"UTD.htm?24/61/25567\">",
"     picture 1",
"    </a>",
"    ). If the anorectal sphincter mechanism is removed with the entire colorectum, a permanent end ileostomy is required (either a standard ileostomy or a continent ileal reservoir). If the anorectal sphincter mechanism is retained, there is the potential for reversal; the trend in management of conditions such as ulcerative colitis or familial polyposis is to remove the diseased colon and rectum and to create an ileal reservoir that is anastomosed to the anorectal sphincter complex.",
"   </p>",
"   <p>",
"    An ileostomy may be constructed either as an end or a loop stoma. A continent ileostomy (Kock pouch) is constructed by detubularizing a segment of terminal ileum and reconfiguring it as a reservoir; the reservoir is connected to an abdominal stoma by a segment of ileum that has been intussuscepted to provide continence. The stoma and reservoir are intubated by the patient on a regular basis to provide elimination of reservoir contents. These continent ileostomies are associated with a fairly high reoperation rate, most commonly due to slippage of the continence mechanism; they are therefore performed on a limited basis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     End ileostomy (Brooke ileostomy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many years an end ileostomy using Brooke's technique (eg, eversion of the bowel to expose the mucosa followed by mucocutaneous suturing to create an end stoma) was the standard management for patients requiring total proctocolectomy for inflammatory bowel disease or familial adenomatous polyposis (",
"    <a class=\"graphic graphic_figure graphicRef72724 \" href=\"UTD.htm?0/31/497\">",
"     figure 1",
"    </a>",
"    ). Brooke's technique is the accepted approach for creation of an end stoma, because it prevents the development of serositis and resultant stricture formation and allows for secure application of the stoma appliance.",
"   </p>",
"   <p>",
"    An end ileostomy is still considered the standard of care for patients with Crohn's disease who require panproctocolectomy; however, patients with benign disease confined to the colon and rectum (eg, ulcerative colitis and familial adenomatous polyposis) have the option of sphincter-sparing surgery and the creation of an ileal reservoir anastomosed to the intact sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. These patients may require a temporary loop ileostomy but do not require a permanent stoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/28\">",
"     28",
"    </a>",
"    ]. An important consideration in surgical construction of an ileostomy is the need for a stoma that protrudes 2 to 3 cm above skin level; a sufficiently \"budded\" stoma supports drainage of the effluent into the pouch and reduces the risk that the enzymatic drainage will leak onto the skin underneath the pouching system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Loop ileostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop ileostomy is frequently used to provide temporary fecal diversion following sphincter-saving rectal resections and ileoanal pouch procedures for patients with ulcerative colitis or familial polyposis (",
"    <a class=\"graphic graphic_figure graphicRef70246 \" href=\"UTD.htm?17/24/17792\">",
"     figure 2",
"    </a>",
"    ). A temporary loop ileostomy is also constructed to provide protection of a distal coloanal or colorectal anastomosis, particularly in patients who have undergone pelvic radiation. Temporary diversion was originally thought to be essential in these situations, to prevent anastomotic breakdown and pelvic sepsis. The diversion itself, however, is associated with some morbidity, and ileostomy closure necessitates an additional surgical procedure. In many centers, temporary diversion is now used only for patients considered high-risk for anastomotic breakdown, including patients with previous radiation to the pelvis, on steroids or other immunologics or biologics, or with very distal anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. When a loop ileostomy is performed, it is usually closed once the anastomosis is well healed, in approximately six weeks to three months following the initial procedure. Though data are inconclusive if immunosuppressive therapy causes a delay in anastomotic healing, many surgeons still protect the primary anastomosis with a temporary ostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loop ileostomies are typically more difficult to manage than end ileostomies because the stoma frequently empties close to the skin surface. A loop ileostomy performed in conjunction with a pelvic pouch procedure is located more proximal in the ileum and is therefore associated with more fluid and enzymatic output. This also may not allow proper absorption of water and vitamins, minerals, and electrolytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Continent ileal reservoir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continent ileal reservoir, originally performed by Nils Kock, involves the creation of an internal reservoir fashioned from detubularized ileum and rendered continent by intussuscepting the segment of ileum connecting the reservoir to the abdominal stoma (",
"    <a class=\"graphic graphic_figure graphicRef66598 \" href=\"UTD.htm?22/33/23056\">",
"     figure 3",
"    </a>",
"    ). The original procedure was modified by Barnett, who added an ileal \"collar\" (a segment of ileum looped around the intussuscepted segment of bowel and connecting to the reservoir) that improves continence (Barnett Continent Ileal",
"    <span class=\"nowrap\">",
"     Reservoir/BCIR).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    primary advantage of the BCIR procedure is that the patient does not wear an external pouch; instead, the reservoir is emptied by intermittent intubation and irrigation. However, the high incidence of complications and the development of the ileal-anal pouch procedure (",
"    <a class=\"graphic graphic_figure graphicRef64517 \" href=\"UTD.htm?1/49/1810\">",
"     figure 4",
"    </a>",
"    ) have significantly reduced the frequency with which this procedure is performed.",
"   </p>",
"   <p>",
"    The continent ileal reservoir is performed only in selected centers by surgeons who specialize in this type of procedure, and it is most commonly limited to patients who desire a continent procedure and are not candidates for an ileal-anal pouch (eg, an ileostomy patient who has previously undergone a non-sphincter sparing panproctocolectomy, or a patient who requires panproctocolectomy and lacks good anal sphincter control) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/23,36,37\">",
"     23,36,37",
"    </a>",
"    ]. A continent ileal reservoir should not be performed in patients with Crohn&rsquo;s disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LIFESTYLE ISSUES",
"    </span>",
"   </p>",
"   <p>",
"    Preoperative patient education is an important component of managing patients who will require a permanent or temporary stoma. Most patients with a stoma are able to have full, healthy, and active social, professional, and sexual lifestyles. In many cases, the quality of life is improved after treating the primary disease, even in light of a permanent ostomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adaptation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient undergoing ostomy surgery must adapt to new patterns of fecal elimination and to a significant alteration in body image. Successful adaptation requires the patient to master new skills and to deal effectively with the many emotional issues associated with loss of the intact body and with altered continence. Interventions that promote adaptation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative stoma site selection by an ostomy nurse or experienced surgeon, to optimize pouch adherence and independence in self-care (the site should be located in the patient's visual field in an area free of creases, scars, or bony prominences)",
"     </li>",
"     <li>",
"      A strong focus on individualized patient education",
"     </li>",
"     <li>",
"      Supportive counseling for all patients and in-depth counseling for any patient who has trouble with adaptation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. A number of studies have demonstrated that involvement of an ostomy nurse specialist (an Enterostomal Therapy nurse, or Wound Ostomy Continence Nurse), particularly preoperatively, has a significant impact on long-term positive outcomes and reduced complication rates, as does involvement in ostomy support groups such as the United Ostomy Association of America [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,37,40-43\">",
"       2,37,40-43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pouching",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first issue to be addressed in successful management of a patient with a standard fecal diversion is selection of an appropriate pouching system for containment of stool and odor and protection of the peristomal skin. There are many pouching systems now available, in both one-piece and two-piece systems. The one-piece systems include a barrier ring with a tape border fused to an odor-proof pouch, while two-piece systems include a barrier ring with a tape border and flange or adhesive landing zone to which the patient attaches a separate odor-proof pouch.",
"   </p>",
"   <p>",
"    One-piece systems offer simplicity and many of these systems provide flexibility, which may be critical for the patient whose stoma is located in a deep crease. Two-piece systems have an advantage for patients who wish to replace the pouch itself without removing the skin barrier.",
"   </p>",
"   <p>",
"    Strategies that help to promote pouch adherence and to minimize leakage include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selection of a pouching system that is compatible with the patient's abdominal contours (eg, a flat pouch with a rigid flange requires a relatively flat pouching surface, while a stoma located in a concave plane is best managed with a convex pouching system to increase protrusion of the stoma and to facilitate drainage of effluent into the pouch).",
"     </li>",
"     <li>",
"      Teaching the patient to size the opening in the pouch to minimize exposed skin.",
"     </li>",
"     <li>",
"      Teaching the patient to empty the pouch when it is about one-third full to prevent excessive weight and potential disruption of the pouch seal.",
"     </li>",
"     <li>",
"      Teaching the patient to change the pouch one to two times weekly and as needed for signs of leakage (itching or burning of the peristomal skin).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Products available to improve the security of the pouch and to minimize damage to the peristomal skin include plasticizing skin \"sealants\" (eg, Skin Prep), skin barrier paste (used to protect any exposed skin and to act as a \"caulking\" agent), adhesive agents, and skin barrier powder (dusted onto any denuded skin to form a protective crust) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Odor and gas management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odor and gas are common concerns for any individual with an ostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/44\">",
"     44",
"    </a>",
"    ]. The patient should be assured that the pouches are odor proof and should be taught simple techniques to keep the \"tail\" of the pouch clean so that it does not become a source of odor (eg, eversion of the \"tail\" of a pouch prior to emptying facilitates easy cleansing and helps prevent odor, as does maintenance of a secure pouch seal). Tail eversion is not required for the newer pouches with integrated closure mechanisms.",
"   </p>",
"   <p>",
"    When the pouch is emptied, odor is normal; room sprays or pouch deodorants can be used to minimize odor with emptying. If odor is a particular concern, the clinician may recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    subgallate or chlorophyllin copper complex; these agents effectively reduce stool odor when taken on a routine basis. Bismuth subgallate tends to thicken the stool so may best be used for the patient with an ileostomy or proximal colostomy; chlorophyllin may have a slight diarrheal effect and is more appropriate for the patient with a",
"    <span class=\"nowrap\">",
"     descending/sigmoid",
"    </span>",
"    colostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gas control strategies include measures to reduce the volume of gas produced or to affect the \"timing\" of flatulence, \"muffling\" measures, and \"venting\" strategies. Dietary modifications and over the counter gas reducing agents are key strategies for reducing the volume of gas. Patients should be given a general list of gas-producing foods. Several foods contain the carbohydrate raffinose, which is poorly digested and leads to gas production by the action of colonic bacteria. Common foods containing raffinose include beans, cabbage, cauliflower, Brussels sprouts, broccoli, and asparagus. Starch and soluble fiber are other forms of carbohydrates that can contribute to gas formation. Potatoes, corn, noodles, and wheat produce gas while rice does not. Soluble fiber (found in oat bran, peas and other legumes, beans, and most fruit) also causes gas (",
"    <a class=\"graphic graphic_table graphicRef64218 \" href=\"UTD.htm?17/25/17821\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=see_link\">",
"     \"Patient information: Gas and bloating (Beyond the Basics)\"",
"    </a>",
"    .) In addition to dietary guidelines, patients should be informed about safe and effective over-the-counter agents that can be used for gas reduction, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"     simethicone",
"    </a>",
"    containing products (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/13/26834?source=see_link\">",
"     Beano",
"    </a>",
"    &reg; and Gas-X&reg;).",
"   </p>",
"   <p>",
"    Patients should also be given an explanation of usual \"lag time\"; the time between ingestion of a gas-producing food and actual flatulence is two to four hours for the ileostomy patient and six to eight hours for the distal colostomy patient. In addition to dietary modifications, ileostomy patients should be taught to avoid drinking through straws, chewing gum, smoking, and chewing with the mouth open, since these measures tend to increase gas ingestion into the proximal bowel.",
"   </p>",
"   <p>",
"    \"Muffling\" measures include layers of clothing and light pressure exerted against the stoma with the hand or arm when flatulence is anticipated. For patients with large volumes of gas, there are pouching systems with filters, which vent and deodorize flatus; there are also \"add-on\" flatus filters that can be used with any pouching system [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Activity issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common concern is the impact of the stoma on activities of daily living. The patient can be reassured that most activities can be safely resumed with minimal if any modifications. As an example, bathing and showering can be performed with the pouch on or off, and clothing modifications are generally not required. Most sports activities can be resumed as well, with the exception of extreme contact sports, which could potentially damage the stoma. The addition of a belt or binder is helpful in maintaining a pouch seal during vigorous activity and perspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity is a particular concern for many patients with an ostomy. As a general rule, the ostomy does not affect organic sexual function. However, in men and women who have had a pelvic dissection, the autonomic nerves controlling sexual function pass along the perirectal tissues and along the sidewalls of the pelvis. During dissection or subsequent to radiation therapy or inflammatory disease processes, these nerves may be injured and function compromised. Men may experience short-term or long-term erectile dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retrograde ejaculation. Women may experience dyspareunia or vaginal dryness following a rectal dissection.",
"   </p>",
"   <p>",
"    Counseling to address questions regarding sexual activity and partner response is critical to rehabilitation of the ostomy patient [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients are cautioned to empty the pouch and assure an intact pouch seal before engaging in sexual activity. In addition, many patients and partners find it helpful to use special lingerie or cummerbunds to conceal and secure the pouch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Traveling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are traveling should be advised to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Take extra supplies, and, if flying, to place them in carry-on luggage.",
"     </li>",
"     <li>",
"      Avoid exposing supplies to extreme temperatures, which may alter the adhesive quality.",
"     </li>",
"     <li>",
"      Drink only water known to be safe if traveling to a foreign country [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diet and fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients assume that they will have to adhere to a special diet because of their ostomy. Although specific foods can influence the amount of the gas and the consistency and odor of the effluent (",
"    <a class=\"graphic graphic_table graphicRef64218 \" href=\"UTD.htm?17/25/17821\">",
"     table 1",
"    </a>",
"    ), dietary modifications are usually minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,46\">",
"     2,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Colostomy patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colostomy patients can be reassured that there are no absolute dietary restrictions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/47\">",
"     47",
"    </a>",
"    ]. However, they should be encouraged to ingest sufficient fiber and fluids to prevent constipation and should also be counseled regarding gas-producing foods and lag time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ileostomy patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ileostomy patients and patients with ascending colostomies should be taught the importance of adequate daily fluid intake. Ileostomy patients should also be taught how to prevent food blockage. Average output for the ileostomy patient ranges from 500 mL to 1300 mL a day; during the early postoperative period and episodes of gastroenteritis, daily output can be 1800 mL or even higher [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients should also be taught the signs and symptoms of fluid-electrolyte imbalance and the importance of prompt treatment should these symptoms occur. These include dry mouth, reduced urine output, dark concentrated urine, feelings of dizziness upon standing, marked fatigue, and abdominal cramping [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,49\">",
"     2,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This increased daily fluid loss places the ileostomy patient at greater risk for dehydration, especially during episodes of increased output or heavy perspiration. Patients should be instructed to increase their daily fluid intake by at least 500 to 750 mL, and to drink even more during periods of high-volume output or heavy sweating. Preferred fluids include sports drinks, broth, and vegetable juices as well as water since ileostomy effluent contains significant amounts of sodium and potassium. Patients should be advised that some sports drinks may not be absorbed and may even exacerbate stoma output and dehydration. The use of pediatric electrolyte solutions, such as PediaLyte&trade;, is preferable to the use of sports drinks.",
"   </p>",
"   <p>",
"    Ileostomy patients should also be taught strategies to prevent food blockage; this can occur because the ileal lumen is &lt;1 inch in diameter and there is the potential for further narrowing at the point where the bowel passes through the",
"    <span class=\"nowrap\">",
"     fascia/muscle",
"    </span>",
"    layer. If the patient consumes large amounts of insoluble fiber, the undigested fiber may create an obstructing mass (bezoar) just proximal to the stoma. Common \"offenders\" include popcorn, coconut, mushrooms, black olives, stringy vegetables, foods with skins, dried fruits, and meats with casings. Food blockage is easily prevented by instructing the patient to add potential offenders one at a time in small amounts, to chew thoroughly, and to monitor their response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,49\">",
"     2,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Issues unique to patients with descending/sigmoid colostomies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues that are unique to individuals with",
"    <span class=\"nowrap\">",
"     descending/sigmoid",
"    </span>",
"    colostomies include the option to manage elimination with routine colostomy irrigation, and management of constipation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management by irrigation involves instillation of 500 to 1500 mL of tap water into the descending or sigmoid colon ostomy on a routine schedule (usually daily or every other day); the resulting distention of the bowel stimulates peristaltic activity, which causes the distal colon to empty. Patients who had fairly normal bowel elimination patterns preoperatively can usually achieve complete evacuation of the colon with irrigation, which provides them with a \"stool-free\" interval of about 24 hours. Most patients who manage their colostomies with routine irrigation are essentially continent and need to wear only a small pouch or \"cap\" for collection of mucous and deodorization of flatus.",
"      <br/>",
"      <br/>",
"      This method of management is appropriate",
"      <strong>",
"       only",
"      </strong>",
"      for patients with distal colostomies and is not effective for all patients. However, patients who manage effectively with routine irrigation report a higher quality of life than patients who manage with pouching [",
"      <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,50-52\">",
"       2,50-52",
"      </a>",
"      ]. Some authorities have raised concerns that routine irrigation could result in bowel dependence; however, colonic distention is a physiologic stimulus to evacuation and there are no studies or data indicating adverse effects.",
"     </li>",
"     <li>",
"      Patients should be taught to prevent constipation by maintaining appropriate fiber and fluid intake. If constipation does occur, it can be managed with laxatives or irrigation. In extreme situations, digital disimpaction may be necessary, but should generally be performed only by an experienced",
"      <span class=\"nowrap\">",
"       physician/surgeon",
"      </span>",
"      or ostomy nurse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Issues unique to the patient with an ileostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with an ileostomy must increase fluid intake to prevent dehydration and must incorporate minor dietary modifications to prevent food blockage. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diet and fluid intake'",
"    </a>",
"    above.) In addition, the patient must exercise particular caution in managing the peristomal skin, since small bowel effluent is rich in proteolytic enzymes. These patients must routinely use barrier wafers, rings,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paste to assure that their skin is not exposed to the drainage and must treat any minor skin damage aggressively to prevent progression. The patient with an ileostomy must be taught to avoid time-released and enteric-coated medications as well as very large tablets, since these forms of medication are likely to be incompletely absorbed. They must also avoid laxatives due to the risk for acute dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal and peristomal complications may occur in the early postoperative period or many years following stomal construction. The most common complication is peristomal skin breakdown; other common complications include parastomal hernia formation, stomal stenosis, retraction, bleeding, and prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/37,53-55\">",
"     37,53-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Peristomal skin breakdown",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peristomal skin irritation most commonly occurs as a result of mechanical trauma, exposure to damaging effluent, or an allergic reaction to a pouching product. Other potential problems include peristomal fungal infections, which are more common in warm and humid climates, and during antibiotic therapy. Peristomal pyoderma gangrenosum, an uncommon ulcerative condition, is sometimes seen in patients with inflammatory bowel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever possible, the patient with peristomal skin problems should be seen by an ostomy nurse specialist. These nurses are skilled in assessing and managing peristomal skin problems. Any refractory peristomal process should prompt a referral to a surgeon or physician with experience and expertise in stoma management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Mechanical trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical trauma typically presents as patchy areas of irritated, denuded skin that result from repeated removal of adhesive products or overly aggressive cleansing techniques. Patients should be taught to use plasticizing skin sealants to help prevent skin damage with pouch removal, and should be cautioned to use a gentle technique when cleaning the peristomal skin.",
"   </p>",
"   <p>",
"    Patients with peristomal hair should be taught to clip the hair to prevent mechanical trauma to the hair follicles. Treatment involves elimination of the causative factors and application of skin barrier powder to the involved areas, followed by blotting with a skin sealant or moistened finger to provide a non-powdery pouching surface [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,37,55\">",
"     2,37,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Effluent contact damage (irritant contact dermatitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to damaging effluent can produce severe skin breakdown in the area exposed to the drainage; this type of skin damage is characterized by severely denuded skin along the inferior aspect of the stoma. Irritant contact dermatitis is most common among ileostomy patients, patients with poorly fitting appliances, and patients with problematic stomas (eg, stomas that are retracted and empty below skin level) (",
"    <a class=\"graphic graphic_picture graphicRef81549 \" href=\"UTD.htm?12/44/12994\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Preventive measures include selection of a pouching system that contours appropriately to the patient's abdomen, correctly sizing the pouch opening to minimize exposed skin, and the use of skin protective products to prevent contact with the drainage.",
"   </p>",
"   <p>",
"    Treatment involves identification and correction of the causative factors, and treatment of the denuded areas with skin barrier powder. If necessary, the powder can be lightly blotted with a moist finger or skin sealant to assure a pouchable surface [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,37,55\">",
"     2,37,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Allergic reactions (allergic contact dermatitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions can occur with any of the products used to protect the peristomal skin or to assure adhesion of the pouching system; allergic reactions are characterized by pruritus, erythema, and blistering in the area corresponding to and demarcated by contact with the offending agent (",
"    <a class=\"graphic graphic_picture graphicRef68947 \" href=\"UTD.htm?39/39/40560\">",
"     picture 3",
"    </a>",
"    ). Treatment primarily involves elimination of the allergen; topical steroids may sometimes be required for a severe reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/2,37,55\">",
"     2,37,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infections present as a maculopapular rash with distinct satellite lesions (",
"    <a class=\"graphic graphic_picture graphicRef79045 \" href=\"UTD.htm?12/9/12433\">",
"     picture 4",
"    </a>",
"    ). These infections are effectively treated with an antifungal powder (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    or miconazole) lightly blotted with a skin sealant to assure a nonpowdery surface for subsequent pouch application [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Peristomal pyoderma gangrenosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peristomal pyoderma gangrenosum is caused by an inflammatory process that produces severe and painful skin ulcerations. While these lesions most commonly occur on the legs, they are also seen in the peristomal area (",
"    <a class=\"graphic graphic_picture graphicRef72285 \" href=\"UTD.htm?36/57/37777\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lesions typically present as full-thickness ulcers, and pain and pathergy are dominant characteristics. The diagnosis is usually one of exclusion, since there is no definitive diagnostic test. If a skin biopsy is performed to rule out other pathology, acute and chronic inflammation is the typical finding. The biopsy should be performed with caution, as this may increase the size of the wound. Granulomas may be noted on microscopic examination.",
"   </p>",
"   <p>",
"    These lesions are managed by systemic, intralesional,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical anti-inflammatory agents, typically steroids. In selected cases where pyoderma is associated with an exacerbation of Crohn's disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    where the pyoderma is refractory to standard treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1 percent topical solution may be applied daily. In severely refractory conditions,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or other immunobiologics may be indicated to treat the underlying systemic pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .) Care must be taken to minimize trauma since pathergy is a prominent feature of these lesions. Dressings should be nonadherent and stoma management should be modified to minimize trauma to the affected area [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/55,57\">",
"     55,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Parastomal hernia formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parastomal hernia formation is a fairly common complication, especially among colostomy patients. The etiologic factors remain obscure, but potential contributing factors include obesity and poor abdominal muscle tone, conditions producing a chronic cough, placement of the stoma outside of the rectus muscle, and a large fascial opening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=see_link\">",
"     \"Parastomal hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most hernias are asymptomatic and do not progress to incarceration. They can be managed effectively with hernia binders that incorporate a cutout for the ostomy pouch [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/55\">",
"     55",
"    </a>",
"    ]. Colostomy patients who manage their stomas with routine irrigation and who develop a hernia should be cautioned to instill the fluid when the hernia is reduced, and to use a cone-tipped irrigating appliance to prevent any damage to the bowel. Surgical repair of the hernia is indicated for pain, intermittent obstruction, acute incarceration, and persistent difficulty with appliance fit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88174825\">",
"    <span class=\"h2\">",
"     Stomal necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal necrosis most commonly occurs in the early postoperative period as a result of venous congestion or arterial insufficiency (eg, tight fascial opening, excessive mesenteric stripping). The most critical assessment is to determine the extent of necrosis, which can be performed by inserting a lubricated test tube into the stoma and using a flashlight to visualize the proximal mucosa. An alternative is to insert a flexible sigmoid.",
"   </p>",
"   <p>",
"    The guidelines for management based upon the clinical setting include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the necrosis extends to the proximal bowel below the anterior fascia, immediate revision is required.",
"     </li>",
"     <li>",
"      If the proximal bowel is viable and the necrosis is limited to the stoma, the observation is appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If necrosis progresses, a revision is required.",
"     </li>",
"     <li>",
"      If sloughing occurs, only gentle debridement may be necessary. Sloughing of the stoma can result in stomal retraction and pouching challenges, but may not require surgical intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Stomal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal stenosis refers to a narrowing of the stoma sufficient to interfere with normal function. Stenosis can occur at the skin or the fascia level. Mild stenosis is asymptomatic and identified only by digital examination of the stoma; clinically significant stenosis usually causes cramping pain followed by explosive output. Mild stenosis can usually be managed by dietary modifications (eg, avoidance of insoluble fiber); gentle routine dilatation of the stoma may also be helpful but is not evidence-based. Clinically significant stenosis usually requires surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/37,55\">",
"     37,55",
"    </a>",
"    ]. Local revision may be the preferred approach, avoiding the complications associated with dilation, including peristomal bleeding, trauma, and promotion of progressive fibrosis and further stenosis. Local repair requires excision of all scar tissue and adequate mobilization with a new tension-free stoma at a relocated site. Enlargement of the skin opening via a double Z-plasty technique may be useful in some situations (eg, limited number of sites for ostomy relocation, limited scarring) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Stomal retraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal retraction can occur immediately postoperatively when abdominal obesity precludes a tension-free anastomosis between the stoma and the skin, early postoperatively as a result of mucocutaneous separation, or late postoperatively as a result of weight gain (",
"    <a class=\"graphic graphic_picture graphicRef81992 \" href=\"UTD.htm?32/37/33375\">",
"     picture 6",
"    </a>",
"    ). Retraction frequently causes major problems with pouch adherence and resultant peristomal skin breakdown.",
"   </p>",
"   <p>",
"    Management usually involves use of a convex pouching system and the addition of a belt or binder. If these measures fail to provide a secure pouch seal, surgical revision may be considered. However, revision is appropriate only when a better outcome can be expected and is not appropriate when the causative factor remains unresolved [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/37,55\">",
"     37,55",
"    </a>",
"    ]. Patients whose retraction is secondary to obesity should be encouraged and assisted to lose weight prior to surgical revision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3285925\">",
"    <span class=\"h2\">",
"     Nipple valve slippage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a Kock pouch or Barnett Continent Ileostomy Reservoir can develop nipple valve slippage, which presents as obstruction or inability to appropriately intubate and evacuate intestinal contents. Surgical management is indicated. Revision may be possible; however, some situations require a resection and reconstruction of a new continent-type ileostomy or a",
"    <span class=\"nowrap\">",
"     traditional/standard",
"    </span>",
"    Brooke end ileostomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Significant stomal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor bleeding can occur with overly vigorous stomal cleansing. Major bleeding from the stoma itself (as opposed to a gastrointestinal bleed) is uncommon and usually indicates either a stomal laceration from a poorly fitting appliance or the development of peristomal varices in the patient with portal hypertension. Initial management of stomal bleeding involves direct pressure and AgNO3 cauterization or suturing of the bleeder if required. Definitive management depends upon the etiology of the bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Peristomal varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peristomal varices are most frequently seen in patients who underwent a colectomy for ulcerative colitis in the setting of primary sclerosing cholangitis. Peristomal varices can also develop in patients with other causes of portal hypertension. Initial management consists of direct pressure followed by injection sclerotherapy or direct suture. However, recurrence is frequent and transjugular intrahepatic portosystemic shunting (TIPS), or, less commonly, a portacaval shunt is advised for select surgical candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/55,59,60\">",
"     55,59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=see_link\">",
"     \"Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding\"",
"    </a>",
"    .) Beta blockers have been effective in controlling variceal bleeding in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Stomal prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal prolapse can occur in patients with elevated intraabdominal pressure. Prolapse is most common in transverse loop colostomies and end descending colostomies.",
"   </p>",
"   <p>",
"    Prolapse presents a management problem but does not compromise bowel integrity or function unless it is significant enough to produce ischemic changes or make appliance placement difficult. Prolapse can be managed conservatively by use of cold compresses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    application of an osmotic agent (eg, table sugar) to reduce edema, followed by manual reduction of the prolapse and application of a binder with a prolapse overbelt to maintain reduction, or by pouching modifications to accommodate the prolapsed bowel when reduction cannot be established or maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/37,55,62\">",
"     37,55,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe prolapse or prolapse producing ischemic changes or severe mucosal irritation and bleeding usually requires surgical intervention. Local revision of the prolapse is accomplished by performing a full-thickness resection of the prolapsed intestinal segment with construction of the stoma at the original site. In the event of a further recurrence, additional bowel resection and relocation of the stoma may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?2/10/2218/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant disease and inflammatory disease can recur at the stoma site or in the bowel proximal to the stoma, and the patient with Crohn's disease may also develop a fistula immediately adjacent to the stoma or proximal to the stoma. Sexually transmitted diseases involving the stoma have been described.",
"   </p>",
"   <p>",
"    Any complaints of stomal pain, lesions on the stoma, or fecal drainage originating from sites other than the ostomy should prompt a thorough evaluation, including biopsy of any stomal lesions. Treatment is based on the underlying disease process and findings after evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Diversion colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diversion colitis is an inflammatory process that occurs in segments of the colorectum that are diverted from the fecal stream by surgery. The most common symptoms in adults are rectal bleeding, tenesmus, mucus discharge, and abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9414?source=see_link\">",
"     \"Diversion colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment may involve instillation of short chain fatty acid (SCFA) enemas, topical steroid enemas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    (5-ASA derivatives) enemas or suppositories. In rare or severe cases of colitis, hyperbaric oxygen is administered or a completion proctectomy and abdominal perineal resection is performed. Reversal of the colostomy when bowel continuity is restored will effectively treat the diversion colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several resources are available for patients who have undergone ostomy. Some of the resources that we have found to be useful are listed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Major product manufacturers",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ConvaTec (full line of one-piece and two-piece pouches, skin protective products, accessories) &ndash; Princeton, NJ, 800-422-8811; www.Convatec.com",
"     </li>",
"     <li>",
"      Hollister (full line of one-piece and two-piece pouches, skin protective products, accessories) &ndash; Libertyville, IL, 800-323-4060; www.Hollister.com",
"     </li>",
"     <li>",
"      Coloplast (one-piece and two-piece pouches, skin protective products) &ndash; Marietta, GA, 800-533-0464; www.us.coloplast.com",
"     </li>",
"     <li>",
"      Marlen (one-piece and two-piece pouches, skin protective products, accessories) &ndash; Bedford, OH, 216-292-7060; www.marlenmfg.com",
"     </li>",
"     <li>",
"      NuHope (one-piece pouches, customized pouching systems, belts and binders, skin protective products) &ndash; Pacoima, CA, 800-899-5017; www.nu-hope.com",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Professional and lay resource groups",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Cancer Society &ndash; Atlanta, GA, 800-ACS-2345;",
"      <a class=\"external\" href=\"file://www.cancer.org/\">",
"       www.cancer.org",
"      </a>",
"     </li>",
"     <li>",
"      Crohn's and Colitis Foundation of America &ndash; New York, NY;",
"      <a class=\"external\" href=\"file://www.ccfa.org/\">",
"       www.ccfa.org",
"      </a>",
"     </li>",
"     <li>",
"      United Ostomy Association of America &ndash; Fairview, TN;",
"      <a class=\"external\" href=\"file://www.uoaa.org/\">",
"       www.uoaa.org",
"      </a>",
"     </li>",
"     <li>",
"      Wound Ostomy Continence Nurses Society &ndash; Mt. Laurel, NJ;",
"      <a class=\"external\" href=\"file://www.wocn.org/\">",
"       www.wocn.org",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"       \"Patient information: Colostomy care (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"       \"Patient information: Colectomy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40882?source=see_link\">",
"       \"Patient information: Ileostomy care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4222432\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal diversions may be required on either a temporary or permanent basis. Fecal diversions are commonly classified according to the segment of the bowel utilized (eg, colon, small bowel)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical construction (eg, loop, end); both location and construction have an impact on management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A colostomy is performed when it is necessary to bypass or remove the distal colon, rectum, or anus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Colostomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An ileostomy is performed when it is necessary to remove or bypass the entire colon and rectum. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ileostomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a colostomy or an ileostomy must adapt to a significant alteration in body image as well as challenges related to odor and gas management, sexual activity, traveling, and dietary limitations. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Lifestyle issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications that can occur include peristomal skin breakdown, parastomal hernia formation, stomal stenosis, and stomal retraction. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Complications'",
"      </a>",
"      above.) A nurse who specializes in the management of ostomies can provide advice to the patient regarding the daily management of an ostomy as well as fit the patient with an appropriately-sized appliance.",
"     </li>",
"     <li>",
"      A surgical revision of an ostomy may be necessary when an ostomy becomes dysfunctional, such as in cases of parastomal herniation, stomal stenosis, or stomal retraction. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/1\">",
"      Doughty D. Principles of ostomy management in the oncology patient. J Support Oncol 2005; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     Erwin-Toth P, Doughty D. Principles and procedures of stomal management. In: Ostomies and Continent Diversions: Nursing Management, Hampton, B, Bryant, R (Eds), Mosby, St. Louis 1992. p.29.",
"    </li>",
"    <li>",
"     Colwell J. Principles of stoma management. In: Colwell, J, Goldberg, M, Carmel, J, Fecal and Urinary Diversions: Management Principles (Ed), Mosby, St. Louis 2004. p.240.",
"    </li>",
"    <li>",
"     Vasilevsky C, Gordon P. Gastrointestinal cancers: Surgical management. In: Fecal and Urinary Diversions: Management Principles, Colwell, J, Goldberg, M, Carmel, J (Eds), Mosby, St. Louis 2004. p.126.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/5\">",
"      G&uuml;enaga KF, Lustosa SA, Saad SS, et al. Ileostomy or colostomy for temporary decompression of colorectal anastomosis. Cochrane Database Syst Rev 2007; :CD004647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/6\">",
"      Rodr&iacute;guez-Ram&iacute;rez SE, Uribe A, Ruiz-Garc&iacute;a EB, et al. Risk factors for anastomotic leakage after preoperative chemoradiation therapy and low anterior resection with total mesorectal excision for locally advanced rectal cancer. Rev Invest Clin 2006; 58:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/7\">",
"      Bowley DM, Boffard KD, Goosen J, et al. Evolving concepts in the management of colonic injury. Injury 2001; 32:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/8\">",
"      Muller-Stich BP, Choudhry A, Vetter G, et al. Preoperative bowel preparation: surgical standard or past? Dig Surg 2006; 23:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/9\">",
"      Demetriades D, Murray JA, Chan L, et al. Penetrating colon injuries requiring resection: diversion or primary anastomosis? An AAST prospective multicenter study. J Trauma 2001; 50:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/10\">",
"      Schilling MK, Maurer CA, Kollmar O, B&uuml;chler MW. Primary vs. secondary anastomosis after sigmoid colon resection for perforated diverticulitis (Hinchey Stage III and IV): a prospective outcome and cost analysis. Dis Colon Rectum 2001; 44:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/11\">",
"      Biondo S, Jaurrieta E, Mart&iacute; Ragu&eacute; J, et al. Role of resection and primary anastomosis of the left colon in the presence of peritonitis. Br J Surg 2000; 87:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/12\">",
"      Murray JA, Demetriades D, Colson M, et al. Colonic resection in trauma: colostomy versus anastomosis. J Trauma 1999; 46:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/13\">",
"      Gonzalez RP, Falimirski ME, Holevar MR. Further evaluation of colostomy in penetrating colon injury. Am Surg 2000; 66:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/14\">",
"      Gooszen AW, Geelkerken RH, Hermans J, et al. Quality of life with a temporary stoma: ileostomy vs. colostomy. Dis Colon Rectum 2000; 43:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/15\">",
"      Rullier E, Le Toux N, Laurent C, et al. Loop ileostomy versus loop colostomy for defunctioning low anastomoses during rectal cancer surgery. World J Surg 2001; 25:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/16\">",
"      Edwards DP, Leppington-Clarke A, Sexton R, et al. Stoma-related complications are more frequent after transverse colostomy than loop ileostomy: a prospective randomized clinical trial. Br J Surg 2001; 88:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/17\">",
"      Sakai Y, Nelson H, Larson D, et al. Temporary transverse colostomy vs loop ileostomy in diversion: a case-matched study. Arch Surg 2001; 136:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/18\">",
"      Rullier E, Zerbib F, Laurent C, et al. Intersphincteric resection with excision of internal anal sphincter for conservative treatment of very low rectal cancer. Dis Colon Rectum 1999; 42:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/19\">",
"      Schiessel R, Rosen HR. Preservation and restoration of sphincter function in patients with rectal cancer. Can J Gastroenterol 2000; 14:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/20\">",
"      Di Betta E, D'Hoore A, Filez L, Penninckx F. Sphincter saving rectum resection is the standard procedure for low rectal cancer. Int J Colorectal Dis 2003; 18:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/21\">",
"      Willis S, Kasperk R, Braun J, Schumpelick V. Comparison of colonic J-pouch reconstruction and straight coloanal anastomosis after intersphincteric rectal resection. Langenbecks Arch Surg 2001; 386:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/22\">",
"      Young M. Caring for patients with coloanal reservoirs for rectal cancer. Medsurg Nurs 2000; 9:193.",
"     </a>",
"    </li>",
"    <li>",
"     Kiran R, Fazio V. Inflammatory bowel disease: Surgical management. In: Fecal and Urinary Diversions: Management Principles, Colwell, J, Goldberg, M, Carmel, J (Eds), Mosby, St. Louis 2004. p.80.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/24\">",
"      Guy TS, Williams NN, Rosato EF. Crohn's disease of the colon. Surg Clin North Am 2001; 81:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/25\">",
"      Seidel SA, Newman M, Sharp KW. Ileoanal pouch versus ileostomy: is there a difference in quality of life? Am Surg 2000; 66:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/26\">",
"      Becker JM. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1999; 28:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/27\">",
"      Beech D, Pontius A, Muni N, Long WP. Familial adenomatous polyposis: a case report and review of the literature. J Natl Med Assoc 2001; 93:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/28\">",
"      Mowschenson PM, Critchlow JF, Peppercorn MA. Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch Surg 2000; 135:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/29\">",
"      Sugerman HJ, Sugerman EL, Meador JG, et al. Ileal pouch anal anastomosis without ileal diversion. Ann Surg 2000; 232:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/30\">",
"      Gullberg K, Liljeqvist L. Gains and losses with stapling and omission of loop ileostomy in pelvic pouch surgery: a matched control study. Int J Colorectal Dis 1999; 14:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/31\">",
"      Bax TW, McNevin MS. The value of diverting loop ileostomy on the high-risk colon and rectal anastomosis. Am J Surg 2007; 193:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/32\">",
"      Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/33\">",
"      Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/34\">",
"      Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/35\">",
"      Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006; 93:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/36\">",
"      Litle VR, Barbour S, Schrock TR, Welton ML. The continent ileostomy: long-term durability and patient satisfaction. J Gastrointest Surg 1999; 3:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/37\">",
"      Colwell JC, Goldberg M, Carmel J. The state of the standard diversion. J Wound Ostomy Continence Nurs 2001; 28:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/38\">",
"      Piwonka MA, Merino JM. A multidimensional modeling of predictors influencing the adjustment to a colostomy. J Wound Ostomy Continence Nurs 1999; 26:298.",
"     </a>",
"    </li>",
"    <li>",
"     White C. Ostomy adjustment. In: Fecal and Urinary Diversions: Management, Colwell, J, Goldberg, M, Carmel, J (Eds), Mosby, St. Louis 2004. p.326.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/40\">",
"      Bass EM, Del Pino A, Tan A, et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 1997; 40:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/41\">",
"      Lyons AS. Ileostomy and colostomy support groups. Mt Sinai J Med 2001; 68:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/42\">",
"      Nugent KP, Daniels P, Stewart B, et al. Quality of life in stoma patients. Dis Colon Rectum 1999; 42:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/43\">",
"      Haugen V, Bliss DZ, Savik K. Perioperative factors that affect long-term adjustment to an incontinent ostomy. J Wound Ostomy Continence Nurs 2006; 33:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/44\">",
"      Annells M. The experience of flatus incontinence from a bowel ostomy: a hermeneutic phenomenology. J Wound Ostomy Continence Nurs 2006; 33:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/45\">",
"      Manderson L. Boundary breaches: the body, sex and sexuality after stoma surgery. Soc Sci Med 2005; 61:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/46\">",
"      Floruta CV. Dietary choices of people with ostomies. J Wound Ostomy Continence Nurs 2001; 28:28.",
"     </a>",
"    </li>",
"    <li>",
"     Black P. Healthy eating. In: Holistic Stoma Care, Bailliere Tindall, 2000. p.177.",
"    </li>",
"    <li>",
"     McCann E. Routine assessment of the patient with an ostomy. In: Wound, Ostomy, and Continence Nursing Secrets, Milne C, Corbett I, Dubuc D (Eds), Hanley and Belfus, Philadelphia 2003.",
"    </li>",
"    <li>",
"     Carmel J, Goldberg M. Preoperative and postoperative management. In: Fecal and Urinary Diversions: Management Principles, Colwell, J, Goldberg, M, Carmel, J (Eds), Mosby, St. Louis 2004. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/50\">",
"      Leong AF, Yunos AB. Stoma management in a tropical country: colostomy irrigation versus natural evacuation. Ostomy Wound Manage 1999; 45:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/51\">",
"      Schaube J, Scharf P, Herz R. [The quality of life after extirpation of the rectum for carcinoma]. Dtsch Med Wochenschr 1996; 121:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/52\">",
"      Woodhouse F. Colostomy irrigation: are we offering it enough? Br J Nurs 2005; 14:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/53\">",
"      Park JJ, Del Pino A, Orsay CP, et al. Stoma complications: the Cook County Hospital experience. Dis Colon Rectum 1999; 42:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/54\">",
"      Shellito PC. Complications of abdominal stoma surgery. Dis Colon Rectum 1998; 41:1562.",
"     </a>",
"    </li>",
"    <li>",
"     Colwell J. Stomal and peristomal complications. In: Fecal and Urinary Diversions: Management Principles, Colwell, J, Goldberg, M, Carmel, J (Eds), Mosby, St. Loius 2004. p.308.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/56\">",
"      Erwin-Toth P. Prevention and management of peristomal skin complications. Adv Skin Wound Care 2000; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/57\">",
"      Kiran RP, O'Brien-Ermlich B, Achkar JP, et al. Management of peristomal pyoderma gangrenosum. Dis Colon Rectum 2005; 48:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/58\">",
"      LYONS AS, SIMON BE. Z-plasty for colostomy stenosis. Ann Surg 1960; 151:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/59\">",
"      Conte JV, Arcomano TA, Naficy MA, Holt RW. Treatment of bleeding stomal varices. Report of a case and review of the literature. Dis Colon Rectum 1990; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/60\">",
"      Roberts PL, Martin FM, Schoetz DJ Jr, et al. Bleeding stomal varices. The role of local treatment. Dis Colon Rectum 1990; 33:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/61\">",
"      Noubibou M, Douala HC, Druez PM, et al. Chronic stomal variceal bleeding after colonic surgery in patients with portal hypertension: efficacy of beta-blocking agents? Eur J Gastroenterol Hepatol 2006; 18:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/62\">",
"      Shapiro R, Chin EH, Steinhagen RM. Reduction of an incarcerated, prolapsed ileostomy with the assistance of sugar as a desiccant. Tech Coloproctol 2010; 14:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/10/2218/abstract/63\">",
"      Shabbir J, Britton DC. Stoma complications: a literature overview. Colorectal Dis 2010; 12:958.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1384 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2218=[""].join("\n");
var outline_f2_10_2218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4222432\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COLOSTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Temporary colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Decompressing colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diverting colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Closure of a temporary colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Permanent colostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ILEOSTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      End ileostomy (Brooke ileostomy)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Loop ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Continent ileal reservoir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LIFESTYLE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adaptation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pouching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Odor and gas management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Activity issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sexual activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Traveling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diet and fluid intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Colostomy patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ileostomy patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Issues unique to patients with descending/sigmoid colostomies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Issues unique to the patient with an ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Peristomal skin breakdown",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Mechanical trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Effluent contact damage (irritant contact dermatitis)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Allergic reactions (allergic contact dermatitis)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Peristomal pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Parastomal hernia formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88174825\">",
"      Stomal necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Stomal stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Stomal retraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3285925\">",
"      Nipple valve slippage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Significant stomal bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Peristomal varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Stomal prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Diversion colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Major product manufacturers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Professional and lay resource groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4222432\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1384|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/31/497\" title=\"figure 1\">",
"      Brooke end ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/24/17792\" title=\"figure 2\">",
"      Loop ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/33/23056\" title=\"figure 3\">",
"      Continent ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/49/1810\" title=\"figure 4\">",
"      Ileal pouch anal anastomosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1384|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/61/25567\" title=\"picture 1\">",
"      Normal ileostomy stoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/44/12994\" title=\"picture 2\">",
"      Colostomy irritant contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/39/40560\" title=\"picture 3\">",
"      Colostomy allergic contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/9/12433\" title=\"picture 4\">",
"      Fungal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/57/37777\" title=\"picture 5\">",
"      Pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/37/33375\" title=\"picture 6\">",
"      Retracted end colostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1384|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/25/17821\" title=\"table 1\">",
"      Diet and stoma function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9414?source=related_link\">",
"      Diversion colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24151?source=related_link\">",
"      Parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=related_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=related_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=related_link\">",
"      Patient information: Gas and bloating (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40882?source=related_link\">",
"      Patient information: Ileostomy care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=related_link\">",
"      Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=related_link\">",
"      Surgical principles of ostomy construction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_10_2219="Features of hyperlactatemia";
var content_f2_10_2219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hyperlactatemia/lactic acidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Nausea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sudden weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Extreme fatigue\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exertional dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmias",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2219=[""].join("\n");
var outline_f2_10_2219=null;
var title_f2_10_2220="Preterm birth rates US";
var content_f2_10_2220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentage of preterm births based on gestational age in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total preterm",
"        <sup>",
"         *",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late preterm",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        32 to 33 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Less than 32 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2011",
"       </td>",
"       <td>",
"        11.72",
"       </td>",
"       <td>",
"        8.28",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        1.92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2008",
"       </td>",
"       <td>",
"        12.33",
"       </td>",
"       <td>",
"        8.77",
"       </td>",
"       <td>",
"        1.57",
"       </td>",
"       <td>",
"        1.98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2005",
"       </td>",
"       <td>",
"        12.73",
"       </td>",
"       <td>",
"        9.09",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        2.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        11.64",
"       </td>",
"       <td>",
"        8.22",
"       </td>",
"       <td>",
"        1.49",
"       </td>",
"       <td>",
"        1.93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1990",
"       </td>",
"       <td>",
"        10.61",
"       </td>",
"       <td>",
"        7.30",
"       </td>",
"       <td>",
"        1.40",
"       </td>",
"       <td>",
"        1.92",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;Preterm is less than 37 completed weeks of gestation.",
"     <br>",
"      &bull;&nbsp;Late preterm is 34 to 36 completed weeks of gestation.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from:",
"     <br>",
"      Martin JA, Hamilton BE, Sutton PD, et al. Births Final data for 2008. Natl Vital Stat Rep 2010.",
"      <a href=\"file://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_05.pdf\">",
"       file://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_05.pdf",
"      </a>",
"      <br>",
"       <br>",
"        Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary data for 2011. Natl Vital Stat Rep 2012.",
"        <a href=\"file://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_05.pdf\">",
"         file://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_05.pdf",
"        </a>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2220=[""].join("\n");
var outline_f2_10_2220=null;
var title_f2_10_2221="Conditions peliosis hepatis";
var content_f2_10_2221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with peliosis hepatis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Drugs and chemicals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2-Chloro-3'-deoxyadenosine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6-mercaptopurine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6-thioguanine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Androgenic-anabolic steroids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arsenic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Azathioprine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cadmium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contraceptive steroids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Danazol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glucocorticoids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tamoxifen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thorium dioxide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urethane",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vinyl chloride",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vitamin A toxicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial endocarditis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bartonella henselae and Bartonella quintana",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human immunodeficiency virus infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leprosy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pyelonephritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syphilis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hematologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Agnogenic myeloid metaplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anaplastic anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Castelman's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fanconi disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hodgkin disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignant histiocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple myeloma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Waldenstr&ouml;m macroglobulinemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Malignancies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colorectal adenocarcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric adenocarcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatocellular carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pancreatic cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prostate cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal cell carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seminoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiac transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic hemodialysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Crohn's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic restrictive cardiomyopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Liver transplant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Marasmus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rheumatoid arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic lupus erythematosus",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2221=[""].join("\n");
var outline_f2_10_2221=null;
var title_f2_10_2222="Symptoms airway disease";
var content_f2_10_2222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Symptoms of upper and lower airways disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 366px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The symptoms of upper and lower airways disease can be directly or indirectly attributed to a dysregulation of airway nerves. See text for details.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2222=[""].join("\n");
var outline_f2_10_2222=null;
var title_f2_10_2223="Colorectal lymphoma BE";
var content_f2_10_2223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-Hodgkin's lymphoma of the colon and terminal ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 220px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Post-evacuation film from a barium enema shows diffuse nodularity of the ileum and entire colon. Histology was consistent with a non-Hodgkin's lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_10_2223=[""].join("\n");
var outline_f2_10_2223=null;
